Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer
Phase: PHASE2
Conditions: Gastroesophageal Cancer
Sponsor: SCRI Development Innovations, LLC

 
CONFIDENTIAL 
This document is confidential and is the property of the SCRI Development Innovations, LLC.  No part of this 
document may be transmitted, reproduced, published, or used by other persons without prior written authorization 
from SCRI Development Innovations, LLC. 
GI 201 
A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line 
Treatment of Patients with Metastatic Gastroesophageal Cancer 
 
SCRI INNOVATIONS STUDY NUMBER: 
 
GI 201 
STUDY DRUG(S): 
Nab-paclitaxel 
SPONSOR: 
SCRI Development Innovations, LLC 
(SCRI Innovations) 
3322 West End Avenue , Suite 900 
Nashville, TN  37203 
1-877-MY-1-SCRI 
asksarah@sarahcannon.com 
 
STUDY CHAIR: 
Johanna Bendell, MD 
Director, GI Oncology Research 
Associate Director, Drug Development Unit 
Sarah Cannon Research Institute   
3322 West End Avenue , Suite 900 
Nashville, TN  37203 
1-877-MY-1-SCRI 
jbendell@tnonc.com 
 
DATE FINAL: 
18 November 2014 

 
 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 2 of 65 
 
 
Clinical Study Statement of Compliance 
A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line 
Treatment of Patients with Metastatic Gastroesophageal Cancer 
 
 This clinical study shall be conducted in compliance with the protocol, as referenced herein, 
and all applicable local, national, and international regulatory requirements to include, but not 
be limited to: 
• 
International Conference on Harmonisation (ICH) Guidelines on Good Clinical 
Practice (GCP) 
• 
Ethical principles that have their origins in the Declaration of Helsinki  
• 
Food and Drug Administration (FDA) Code of Federal Regulation (CFR): 
o 
Title 21CFR Part 50 & 45 CFR Part 46, Protection of Human Subjects 
o 
Title 21CFR Part 54, Financial Disclosure by Clinical Investigators 
o 
Title 21CFR Part 56, Institutional Review Boards 
o 
Title 21CFR Part 312, Investigational New Drug Application 
o 
Title 45 CFR Parts 160, 162, and 164, Health Insurance Portability and 
Accountability Act (HIPAA)  
 
As the Study Chair and/or Principal Investigator, I understand that my signature on the 
protocol constitutes my agreement and understanding of my responsibilities to conduct the 
clinical study in accordance to the protocol and applicable regulations.  Furthermore, it 
constitutes my understanding and agreement that any changes initiated by myself, without 
prior agreement in writing from SCRI Innovations, shall be defined as a deviation from the 
protocol, and shall be formally documented as such. 
 

 
 
 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 3 of 65 
 
Clinical Study Signature Approval Page 
A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line 
Treatment of Patients with Metastatic Gastroesophageal Cancer 
 
SCRI INNOVATIONS STUDY NUMBER: 
 
GI 201 
STUDY DRUG(S): 
Nab-paclitaxel  
DATE FINAL: 
18 November 2014 
 
 
__________________________ 
__________________________         ______________  
Study Chair 
 
Study Chair Signature 
 
Date 
 
 
 
 
 
__________________________ 
__________________________         ______________  
SCRI Development Innovations, LLC 
 
 
SCRI Development Innovations, LLC  
Representative Signature 
 
Date 
 
 
 
Johanna Bendell, MD 
Sheetal Khedkar 

 
 
 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 4 of 65 
 
 
Clinical Study Principal Investigator Signature Form 
A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line 
Treatment of Patients with Metastatic Gastroesophageal Cancer 
 
SCRI INNOVATIONS STUDY NUMBER: 
 
GI 201 
DATE FINAL: 
18 November 2014 
 
 
By signing this protocol acceptance page, I confirm I have read, understand, and agree to conduct the 
study in accordance with the current protocol. 
 
 
 
__________________________ _            _______________________________     _______  
Principal Investigator Name 
(Please Print) 
 
Principal Investigator Signature 
 
Date 
 
Please retain a copy of this page for your study files and return the original signed and dated 
form to: 
 
SCRI Development Innovations, LLC 
3322 West End Avenue, Suite 900 
Attn:  GI 201 Study Team  
Nashville, TN 37203 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 5 of 65 
 
GI 201 PROTOCOL SYNOPSIS 
Title of Study: 
A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line Treatment of 
Patients with Metastatic Gastroesophageal Cancer 
SCRI Innovations 
Study Number: 
GI 201 
Sponsor: 
SCRI Development Innovations, LLC – Nashville - TN 
Study Duration: 
The total duration of the study is planned to be 27 months 
Phase of Study:  II 
Study Centers: 
This study will be conducted at multiple sites. 
Number of 
Patients: 
Up to 65 patients are planned to be enrolled in this study. 
Objectives: 
Primary Objective 
The primary objective of this study is to: 
• 
Determine the progression free survival (PFS) of patients receiving nab-paclitaxel 
in combination with ramucirumab as second-line therapy for metastatic 
gastroesophageal (GE) cancer. 
Secondary Objectives 
The secondary objectives of this study are to: 
• 
Evaluate other efficacy measurements of this regimen (response rate [RR], time to 
progression [TTP], and overall survival [OS]) of nab -paclitaxel plus ramucirumab 
as second-line therapy for metastatic gastroesophageal cancer 
• 
Further evaluate toxicities associated with this regimen in patients with metastatic 
GE cancer. 
Study Design: 
This is a Phase II, open-label, non-randomized study.  Patients will be given nab-paclitaxel 
by IV at a dose of 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle (weekly for 3 weeks 
with 1 week of rest) in combination with ramucirumab 8 mg/kg IV on Days 1 and 15.  
Restaging will occur every 2 cycles (8 weeks), and patients with an objective response or 
stable disease will remain on study until evidence of progressive disease or unacceptable 
toxicity.   
Study Drugs, 
Doses, and Modes 
of Administration: 
Nab-paclitaxel 125 mg/m2 IV  
Ramucirumab 8 mg/kg IV 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 6 of 65 
 
 
GI 201 PROTOCOL SYNOPSIS 
Inclusion Criteria: 
Patients must meet all the following criteria in order to be included in the research study: 
1. Histologically confirmed metastatic adenocarcinoma of the esophagus, GE junction, or 
stomach that is not responsive to standard therapies. 
2. Measurable disease as measured by Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria Version 1.1 (Appendix E). 
3. Patients must have progressed on one prior line of chemotherapy in the metastatic setting 
• Patients will be allowed to have had previous neoadjuvant and/or adjuvant 
chemotherapy or chemoradiation therapy as long as treatment was completed > 6 
months prior to diagnosis of metastatic disease.  The neoadjuvant or adjuvant 
therapy in this setting will not be counted as a line of therapy in the metastatic or 
advanced setting. 
• Patients who develop metastatic disease or worsening of localized disease within 
6 months of the completion of neoadjuvant or adjuvant therapy will have the 
neoadjuvant or adjuvant therapy count as one line of therapy in the advanced setting.   
• Previous radiation therapy alone or in combination with single agent 
fluoropyrimidine (5-FU, capecitabine) in the localized or palliative setting will not 
count as a line of therapy. 
4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 
(Appendix A). 
5. Adequate hematologic function defined as: 
- 
Absolute neutrophil count (ANC) ≥1500/mm3 
- 
Hemoglobin (Hgb) >9 g/dL 
- 
Platelets >100,000/mm3 
6. Adequate liver function defined as: 
- 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
≤2.5 x the upper limit of normal (ULN)  
- 
Alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis 
is present in the absence of liver metastasis 
- 
Total bilirubin ≤1.5 x ULN (unless the patient has Grade 1 bilirubin 
elevation due to Gilbert’s disease or a similar syndrome involving slow conjugation 
of bilirubin) 
7. Adequate renal function defined as serum creatinine ≤1.5 mg/dL (133 μmol/L) OR 
calculated creatinine clearance >40 mL/min as calculated by Cockcroft and Gault 
Formula. 
8. Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer 
Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03) 
9. Women of childbearing potential must have a negative serum or urine pregnancy test 
performed ≤7 days prior to start of treatment.  If a woman becomes pregnant or suspects 
she is pregnant while participating in this study, she must agree to inform her treating 
physician immediately. 
10. Male patients with female partners of childbearing potential and women patients of 
childbearing potential are required to use two forms of acceptable contraception, 
including one barrier method, during their participation in the study and for 6 months 
following last dose of study drug(s).  Male patients must also refrain from donating 
sperm during their participation in the study (Appendix C). 
11. Life expectancy > 3 months. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 7 of 65 
 
GI 201 PROTOCOL SYNOPSIS 
Inclusion 
Criteria, 
continued 
12. Age ≥18 years. 
13. Willingness and ability to comply with study and follow-up procedures. 
14. Ability to understand the nature of this study and give written informed consent. 
Exclusion 
Criteria: 
1. Patients who have received any other investigational agents, chemotherapy, biologic 
therapy, or radiation therapy within the 28 days prior to Day 1 of the study.  For 
investigational, chemotherapy, or biologic therapy, patients will be allowed on study if 
5 half- lives or greater have elapsed since last dose of drug or 28 days, whichever is 
shorter.   
2. History of other carcinomas (in situ and invasive) within the last five years that, in the 
investigator’s opinion, may affect interpretation of the endpoints of this study. 
3. Patients with other concurrent severe and/or uncontrolled medical disease which could 
compromise safety of treatment as so judged by treating physician (i.e., severely 
impaired lung function, severe infection, ventricular arrhythmias active ischemic heart 
disease, known active vasculitis of any cause, chronic liver or renal disease). 
4. Patients with prior taxane chemotherapy. 
5. A known history of HIV seropositivity, hepatitis C virus, acute or chronic active 
hepatitis B infection, or other serious chronic infection requiring ongoing IV treatment. 
6. Women who are pregnant or breast-feeding 
7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, or psychiatric illness/social situations that would limit safety or compliance 
with study requirements or may interfere with the interpretation of the results.. 
8. Inadequately controlled hypertension (blood pressure [BP]>150 systolic and/or 
diastolic >100 mmHg) (patients with values above these levels must have their BP 
controlled with medication prior to starting treatment). 
9. Any of the following cardiac diseases currently or within the last 6 months: 
- 
Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated 
Acquisition (MUGA) scan or echocardiogram (ECHO) 
- 
QTc interval >480 ms on screening electrocardiogram (ECG) per institutional 
standard 
- 
Unstable angina pectoris 
- 
Congestive heart failure (New York Heart Association (NYHA) ≥ Grade 2 
[Appendix B]) 
- 
Acute myocardial infarction 
- 
Clinically significant conduction abnormality not controlled with pacemaker or 
medication 
- 
Significant ventricular or supraventricular arrhythmias (patients with chronic rate-
controlled atrial fibrillation in the absence of other cardiac abnormalities are 
eligible) 
- 
Valvular disease with significant compromise in cardiac function 
10. History of hypertensive crisis or hypertensive encephalopathy. 
11. History of stroke or transient ischemic attack (TIA) within the past 6 months. 
12. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent 
peripheral arterial thrombosis) within 6 months prior to initiation of therapy. 
13. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess 
within the past 6 months. 
14. Patients may not have received other agents, either investigational or marketed, which 
act by primary anti-angiogenic mechanisms.  

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 8 of 65 
 
GI 201 PROTOCOL SYNOPSIS 
 
Exclusion 
Criteria, 
continued 
15.  Major surgical procedure, open biopsy; or significant traumatic injury within 28 days 
prior to study initiation, or anticipation of need for major surgical procedure during the 
course of the study. 
16. Core biopsy or other minor surgical procedure, excluding placement of a vascular 
access device, within 7 days prior to initiation of therapy. 
17. Patients with proteinuria, as demonstrated by a Urine Protein on dipstick of 2+ or 
greater at screening. 
18. Any non-healing wound, ulcer, or bone fracture. 
19. Any clinical evidence or history of a bleeding diathesis or significant coagulopathy (in 
the absence of therapeutic anticoagulation). 
20. Therapeutic anticoagulation with coumarin-derivatives will not be permitted.  
However, a maximum daily dose of 1 mg will be permitted for port line patency.  
Anticoagulation with low molecular weight heparin or anti-Factor Xa agents will be 
allowed. 
21. History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month 
prior to initiation of therapy. 
Statistical 
Methodology: 
This is a Phase II, open-label, non-randomized study.  The study is designed to determine 
the PFS of nab-paclitaxel in combination with ramucirumab for patients as second-line 
therapy for metastatic gastroesophageal cancer. 
The historical median PFS is 2.8 months; we hypothesize that nab-paclitaxel plus 
ramucirumab will increase median PFS to 5 months.  With a 2-sided alpha of 5% and 80% 
power, a total of 52 events (progressions or deaths) will need to be observed.  With an 18-
month recruitment and 6 months follow-up, assuming 20% of patients recruited will be free 
from progression or death at the end of the study, 65 patients will need to be recruited into 
the study in order to observe 52 events. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 9 of 65 
 
GI 201 CONTACT INFORMATION 
SCRI Innovations 
Contact Information: 
SCRI Innovations 
3322 West End Avenue, Suite 900 
Nashville, TN  37203 
1-877-MY-1-SCRI 
asksarah@sarahcannon.com 
 
Study Chair: 
Johanna Bendell, MD 
Sarah Cannon Research Institute 
3322 West End Avenue, Suite 900 
Nashville, TN  37203 
1-877-MY-1-SCRI 
asksarah@sarahcannon.com 
 
Safety Dept. Fax #: 
Safety Dept. Email: 
1-866-807-4325 
CANN.SAE@SCRI-Innovations.com 
Regulatory Phone #   
Regulatory Email: 
1-877-MY-1-SCRI  
SCRIRegulatory@SCRI-Innovations.com 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 10 of 65 
 
LIST OF ABBREVIATIONS 
AE 
Adverse event 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
ANC 
Absolute neutrophil count 
AR 
Adverse reaction 
AST 
Aspartate aminotransferase 
BP 
Blood pressure 
BUN 
Blood urea nitrogen 
CBC 
Complete blood count 
CFR 
Code of Federal Regulations 
CEA 
Carcinoembryonic antigen 
CI 
Confidence interval 
CMP 
Comprehensive metabolic profile 
CO2 
Carbon dioxide 
CR 
Complete response/remission 
CT 
Computerized tomography 
DCR 
Disease control rate 
DHEA 
Dehydroepiandrosterone 
ECG 
Electrocardiogram 
ECHO 
Echocardiogram 
ECOG  
Eastern Cooperative Oncology Group  
eCRF 
electronic Case Report Form 
FDA 
Food and Drug Administration 
FSH 
Follicle stimulating hormone 
GCP 
Good Clinical Practice 
G-CSF 
Granulocyte colony-stimulating factor 
GE 
Gastroesophageal 
Hgb 
Hemoglobin 
HIPAA 
Health Insurance Portability and Accountability Act 
HR 
Hazard ratio 
IB 
Investigator’s Brochure 
ICF 
Informed consent form 
ICH 
International Conference on Harmonization 
INR 
International Normalized Ratio 
IRB 
Institutional Review Board 
ISF 
Investigator study file 
IV 
Intravenous 
LVEF 
Left ventricular ejection fraction 
MedDRA 
Medical Dictionary for Regulatory Activities 
MRI 
Magnetic resonance imaging 
MTD 
Maximum tolerated dose 
MUGA 
Multiple gated acquisition 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 11 of 65 
 
LIST OF ABBREVIATIONS (continued) 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NYHA 
New York Heart Association 
OR 
Objective response 
ORR 
Overall response rate 
OS 
Overall survival 
PD 
Progressive disease 
PDx 
Pharmacodynamic 
PHI 
Protected health information 
PFS 
Progression-free survival 
PK 
Pharmacokinetic 
PR 
Partial response/remission 
PT 
Prothrombin Time 
PTT 
Partial Thromboplastin Time 
QA 
Quality assurance 
RECIST 
Response Evaluation Criteria in Solid Tumors 
RR 
Response rate 
SAE 
Serious adverse event 
SAR 
Suspected adverse reaction 
SCRI 
Sarah Cannon Research Institute 
SCRI Innovations SD 
SCRI Innovations Safety Department 
SD 
Stable disease 
SPARC 
Secreted protein acidic and rich in cysteine 
SUSAR 
Suspected unexpected serious adverse reaction 
TIA 
Transient ischemic attack 
TTP 
Time to progression 
UAE 
Unexpected Adverse Event 
ULN 
Upper limit of normal 
USPI 
US package insert 
VEGF-2 
Vascular endothelial growth factor receptor-2 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 12 of 65 
 
TABLE OF CONTENTS 
1. 
INTRODUCTION ................................................................................................. 16 
1.1 
Background ........................................................................................................... 16 
1.2 
Treatment for Metastatic Gastroesophageal Tumors ............................................ 16 
1.3 
Nab-paclitaxel ....................................................................................................... 17 
1.4 
Ramucirumab ........................................................................................................ 18 
1.5 
Rationale for the Study .......................................................................................... 19 
2. 
STUDY OBJECTIVES ......................................................................................... 19 
2.1 
Primary Objective.................................................................................................. 19 
2.2 
Secondary Objectives ............................................................................................ 19 
3. 
STUDY PATIENT POPULATION AND DISCONTINUATION ...................... 19 
3.1 
Inclusion Criteria ................................................................................................... 19 
3.2 
Exclusion Criteria .................................................................................................. 21 
3.3 
Discontinuation from Study Treatment ................................................................. 22 
4. 
STUDY REGISTRATION.................................................................................... 23 
5. 
STUDY DESIGN .................................................................................................. 23 
5.1 
Treatment Plan ...................................................................................................... 25 
5.1.1 
Nab-paclitaxel ....................................................................................................... 25 
5.1.2 
Ramucirumab ........................................................................................................ 25 
5.2 
Treatment Duration ............................................................................................... 25 
5.3 
Concomitant Medications...................................................................................... 25 
5.3.1 
Permitted Concomitant Medications ..................................................................... 25 
5.3.2 
Prohibited Concomitant Medications .................................................................... 26 
6. 
DOSE MODIFICATIONS .................................................................................... 26 
6.1 
Dose Modifications Due to Hematologic Toxicity ............................................... 27 
6.1.1 
Administration of Nab-Paclitaxel to Patients with Abnormal Hematologic 
Function ................................................................................................................. 27 
6.1.2 
Dose Reductions and Guidelines for Optional use of Growth Factors for 
Hematologic Toxicity ............................................................................................ 27 
6.2 
Dose Modifications Due to Non-Hematologic Toxicity ....................................... 28 
6.2.1 
Nab-Paclitaxel Non-Hematologic Dose Modifications ......................................... 28 
6.2.2 
Ramucirumab Non-Hematologic Toxicity ............................................................ 29 
7. 
STUDY ASSESSMENTS AND EVALUATIONS .............................................. 32 
7.1 
Overview ............................................................................................................... 32 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 13 of 65 
 
7.2 
Baseline Study Assessments ................................................................................. 33 
7.3 
Study Treatment Assessments ............................................................................... 33 
7.3.1 
Day 1 of each cycle (+/- 72 hours) ........................................................................ 33 
7.3.2 
Day 8 and 15 of each cycle ................................................................................... 34 
7.4 
Response Assessment Every 2 Cycles .................................................................. 34 
7.5 
End-of-Study Treatment ........................................................................................ 34 
7.6 
Follow-up .............................................................................................................. 35 
7.6.1 
Follow-up for Patients Who Discontinue Prior to Disease Progression ............... 35 
7.6.2 
Survival Follow-Up ............................................................................................... 35 
8. 
DRUG FORMULATION, AVAILABILITY, ADMINISTRATION, AND 
TOXICITY INFORMATION ............................................................................... 35 
8.1 
Nab-Paclitaxel ....................................................................................................... 35 
8.1.1 
Labeling, Packaging, and Supply .......................................................................... 35 
8.1.2 
Preparation and Administration of Nab-paclitaxel ................................................ 35 
8.1.3 
Precautions and Risks Associated with Nab-paclitaxel ........................................ 36 
8.2 
Ramucirumab ........................................................................................................ 36 
8.2.1 
Labeling, Packaging, and Supply .......................................................................... 36 
8.2.2 
Preparation and Administration of Ramucirumab................................................. 36 
8.2.3 
Precautions and Risks Associated with Ramucirumab ......................................... 36 
8.3 
Accountability for All Study drugs ....................................................................... 36 
9. 
RESPONSE EVALUATIONS AND MEASUREMENTS .................................. 36 
10. 
STATISTICAL CONSIDERATIONS .................................................................. 37 
10.1 
Statistical Design ................................................................................................... 37 
10.2 
Sample Size Considerations .................................................................................. 37 
10.3 
Analysis Populations ............................................................................................. 37 
10.4 
Data Analysis ........................................................................................................ 37 
10.4.1 
Demographics and Baseline Characteristics ......................................................... 38 
10.4.2 
Efficacy Analysis .................................................................................................. 38 
10.4.3 
Safety Analysis ...................................................................................................... 39 
10.5 
Analysis Time Points............................................................................................. 39 
10.5.1 
Final Analysis ........................................................................................................ 39 
10.5.2 
Safety Review........................................................................................................ 39 
10.5.3 
Efficacy Review .................................................................................................... 39 
11. 
SAFETY REPORTING AND ANALYSES ......................................................... 39 
11.1 
Definitions ............................................................................................................. 40 
11.1.1 
Adverse Events ...................................................................................................... 40 
11.1.2 
Serious Adverse Event .......................................................................................... 40 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 14 of 65 
 
11.1.3 
Adverse Reaction .................................................................................................. 41 
11.1.4 
Suspected Adverse Reaction ................................................................................. 41 
11.1.5 
Recording and Reporting of Adverse Events ........................................................ 41 
11.1.6 
Assessment of Adverse Events.............................................................................. 42 
11.2 
Serious Adverse Event Reporting by Investigators ............................................... 42 
11.3 
Recording of Adverse Events and Serious Adverse Events .................................. 43 
11.3.1 
Diagnosis versus Signs and Symptoms ................................................................. 43 
11.3.2 
Persistent or Recurrent Adverse Events ................................................................ 43 
11.3.3 
Abnormal Laboratory Values ................................................................................ 44 
11.3.4 
Deaths .................................................................................................................... 44 
11.3.5 
Hospitalization, Prolonged Hospitalization, or Surgery ........................................ 44 
11.3.6 
Pre-Existing Medical Conditions .......................................................................... 45 
11.3.7 
New Cancers.......................................................................................................... 45 
11.3.8 
Pregnancy, Abortion, Birth Defects/Congenital Anomalies ................................. 45 
11.4 
SCRI Innovations Safety Department Serious Adverse Event Reporting 
Requirements ......................................................................................................... 45 
11.4.1 
SCRI Innovations Safety Department Assessment of Unexpected ....................... 46 
11.4.2 
Sponsor Reporting for Clinical Studies Under an Investigational New Drug 
Application ............................................................................................................ 47 
12. 
QUALITY ASSURANCE AND QUALITY CONTROL .................................... 47 
12.1 
Study Monitoring, Auditing, and Inspecting ......................................................... 47 
13. 
ETHICAL, FINANCIAL, AND REGULATORY CONSIDERATIONS ............ 47 
13.1 
Institutional Review Board Approval.................................................................... 48 
13.2 
Regulatory Approval ............................................................................................. 48 
13.3 
Informed Consent .................................................................................................. 48 
13.3.1 
Confidentiality ....................................................................................................... 49 
13.4 
Financial Information ............................................................................................ 50 
14. 
RESEARCH RETENTION AND DOCUMENTATION OF THE STUDY ........ 50 
14.1 
Amendments to the Protocol ................................................................................. 50 
14.2 
Documentation Required to Initiate the Study ...................................................... 50 
14.3 
Study Documentation and Storage ........................................................................ 51 
14.4 
Data Collection ...................................................................................................... 53 
14.5 
Disclosure and Publication Policy ......................................................................... 53 
15. 
REFERENCES ...................................................................................................... 54 
16. 
APPENDICES ....................................................................................................... 56 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 15 of 65 
 
LIST OF TABLES 
Table 1 
Dose Level Modifications ........................................................................ 27 
Table 2 
Use of G-CSF and Nab-paclitaxel Dose Reductions for Hematologic 
Toxicity .................................................................................................... 28 
Table 3 
Other Ramucirumab Non-Hematological Toxicities ............................... 32 
LIST OF FIGURES 
Figure 1 
Mechanism of transport and accumulation of nab-paclitaxel in tumor 
cells .......................................................................................................... 18 
Figure 2 
Study Schema........................................................................................... 24 
LIST OF APPENDICES 
Appendix A: 
ECOG Performance Status Criteria ......................................................... 56 
Appendix B: 
New York Heart Association (NYHA) Classification of Cardiac 
Disease ..................................................................................................... 57 
Appendix C: 
Guidelines for Female Patients of Childbearing Potential and Fertile 
Male Patients ............................................................................................ 58 
Appendix D: 
Schedule of Assessments ......................................................................... 60 
Appendix E: 
Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1... 62 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 16 of 65 
 
1. 
INTRODUCTION 
1.1 
Background 
Adenocarcinoma of the esophagus and the gastroesophageal junction (GE junction) is the ninth 
most common cancer worldwide.  Late mortality rate is high with only 8% of patients surviving 
more than five years with a median survival of nine months.  Esophageal carcinoma affects adult 
patients in all ages with no difference in survival according to sex, racial background, or 
histological type.  Over the past two decades, a shift in the incident and lethality of the gastric 
cancer has been noted in the Western countries. While incidents of distal gastric cancers have 
decreased, the incidence of adenocarcinomas of the proximal stomach and distal esophagus has 
increased (Blot et al. 1991; Pera et al. 1993; Devesa et al. 1998).  In addition, the unique 
behavior of these proximal tumors makes them challenging to treat. These tumors are often 
located at the crossroads of two major body cavities; therefore, the lymphatic spread of the 
disease may occur in two directions—proximally into the mediastinum and distally to the celiac 
lymph nodes (Lerut et al. 2004). As a result, these tumors remain undiagnosed at an early stage 
and patients often present with a relatively advanced stage disease (Ajani et al. 2004). 
1.2 
Treatment for Metastatic Gastroesophageal Tumors 
A multitude of trials in the metastatic setting exist for both esophageal and gastric 
adenocarcinoma, the preponderance including GE junctional tumors.  Despite this abundance, 
there is no regimen in either disease that can achieve more than marginal success or superiority.  
As with most chemotherapy, combination regimens seem to be better for initial response, but this 
does not necessarily translate into survival. 
Currently, multiple regimens are used in the treatment of metastatic esophagogastric cancers.  
These include: cisplatin and fluorouracil (5-FU) or CF, epirubicin, cisplatin, and 5-FU (ECF), 
epirubicin, oxaliplatin, and 5-FU (EOX), cisplatin and irinotecan, docetaxel, cisplatin, and 5-FU 
(DCF).  The current United States Food and Drug Administration (FDA) standard comparator 
regimen is a combination of 5-FU and cisplatin.  Until recently, there was no FDA standard 
comparator except best supportive care in the second line setting.  There is data on the efficacy 
of taxane-based therapy in the second-line setting after progression on a prior platinum-based 
regimen.  Studies have shown response rates of second line paclitaxel or docetaxel to range from 
20% to 30%.  Trials evaluating docetaxel or paclitaxel in this setting have shown time to 
treatment failure rates in the range of 2-5 months.  The COUGAR trial was a randomized Phase 
III study that randomized second-line gastric cancer patients to docetaxel every three weeks or 
best supportive care.  Patients who received docetaxel had an improved overall survival (OS) of 
5.2 months compared to 3.6 months (hazard ration [HR] 0.67).  Response rate (RR) to docetaxel 
was 7% (Ford et al. 2012).  A recent randomized Phase III study of the anti-vascular endothelial 
growth factor receptor-2 (VEGFR2) antibody ramucirumab versus best supportive care for 
second-line treatment of gastric cancers showed an improved OS akin to docetaxel (5.2 vs. 2.6 
months) and improved progression-free survival (PFS) (2.1 vs. 1.3 months) (Fuchs et al. 2012).  
Given the utilization of taxanes as second-line therapy, the RAINBOW study evaluated weekly 
paclitaxel plus or minus ramucirumab.  This study showed an improvement in PFS (4.40 vs. 2.86 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 17 of 65 
 
months, HR 0.635) and OS (9.63 vs. 7.63 months, HR 0.807) for patients who received the 
combination of paclitaxel and ramucirumab (Wilke et al. 2014).  The FDA approved 
ramucirumab for treatment of patients in the second-line setting in April 2014. 
1.3 
Nab-paclitaxel 
Nab-paclitaxel (Abraxane® [ABI-007]) is a proprietary solvent-free, protein-stabilized 
formulation of paclitaxel, which also contains human albumin in a noncrystalline amorphous 
state, with a mean particle size of approximately 130 nanometers.  Paclitaxel enhances the 
polymerization of tubulin to stable microtubules and also interacts directly with microtubules, 
stabilizing them against depolymerisation.  The highly stable tubulin complexes lead to the 
formation of discordant and dysfunctional microtubule arrays, visible as "bundles" during mitotic 
cell division and results in apoptosis and cell death.  Nab-paclitaxel has a similar mode of action 
and was developed to improve the therapeutic index and reduce toxicity, and can be administered 
via the intravenous (IV) route.   
Nab-paclitaxel uses a receptor-mediated transport process allowing transcytosis across the 
endothelial cell wall, thereby breaching the blood/tumor interface.  This albumin-specific 
receptor mediated process involves the binding of a specific receptor (gp60) on the endothelial 
cell wall, resulting in the activation caveolin-1, which initiates an opening in the endothelial wall 
with formation of a little caves or caveolae, with transport of the albumin-bound 
chemotherapeutic complex via these caveolae to the underlying tumor interstitium.  A protein 
specifically secreted by the tumor (SPARC) binds and entraps the albumin, allowing release of 
the hydrophobic drug to the tumor cell membrane.  Nab-paclitaxel is the first biologically 
interactive nanoparticle that exploits the gp-60/caveolin-1/SPARC pathway to enhance intra-
tumoral concentration of the drug thereby significantly reducing normal tissue toxicity.  Clinical 
studies have demonstrated less toxicity with nab-paclitaxel compared to solvent-based paclitaxel.  

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 18 of 65 
 
Figure 1 
Mechanism of transport and accumulation of nab-paclitaxel in tumor cells  
 
As of October 2013, nab-paclitaxel has been approved in over 40 countries/regions, for the 
treatment of patients with metastatic breast cancer, as well as for the first-line treatment of 
locally advanced or metastatic non-small cell lung cancer (NSCLC) and metastatic 
adenocarcinoma of the pancreas. 
1.4 
Ramucirumab 
Angiogenesis is required for cancer progression and establishment of metastatic lesions in distant 
organs.  Vascular endothelial growth factor receptor-2 (VEGFR-2) is considered a key factor in 
cancer-associated angiogenesis, and is substantially expressed and associated with negative 
prognostic features in gastroesophageal and other cancers.  Anti-VEGFR-2 antibodies have been 
shown to inhibit VEGF-stimulated receptor activation and proliferation of human leukemia cells 
(Lu et al. 2002; Lu et al. 2003).  Therefore, these antibodies hold promise for further therapeutic 
application in other types of cancers including solid tumors and hematologic tumors, such as 
leukemia and lymphomas.  
Ramucirumab (IMC-1121B [LY3009806]) is a recombinant human monoclonal antibody that 
specifically binds to the extracellular domain of the VEGFR-2.  The binding of ramucirumab to 
VEGFR-2 prevents its interaction with activating ligands (VEGF-A, VEGF-C, and VEGF-D) 
and blocks activation of VEGFR-2 and its downstream intracellular signaling components, 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 19 of 65 
 
including p44/p42 mitogen-activated protein kinases, inhibiting ligand-induced proliferation and 
migration of human endothelial cells. 
1.5 
Rationale for the Study 
The REGARD trial (Fuchs et al. 2012) showed that ramucirumab was beneficial in patients with 
cancers of the esophagus and stomach.  The RAINBOW trial (Wilke et al. 2014) demonstrated a 
beneficial effect on the OS when ramucirumab plus paclitaxel was used, compared to paclitaxel 
alone.  However, neutropenia was more frequently reported in the combination arm.   
The Phase II study we propose uses an albumin-based formulation of paclitaxel, which may 
potentially increase the tumor uptake of the drug, improving efficacy and minimizing the side 
effects.  The biological rationale of using this combination is that ramucirumab will inhibit tumor 
angiogenesis and nab-paclitaxel will induce apoptosis of the rapidly dividing tumor cell.  
2. 
STUDY OBJECTIVES 
2.1 
Primary Objective 
The primary objective of this study is to: 
• Determine the progression-free survival (PFS) of patients receiving nab-paclitaxel in 
combination with ramucirumab as second-line therapy for metastatic gastroesophageal 
cancer. 
2.2 
Secondary Objectives 
The secondary objectives of this study are to: 
• Evaluate other efficacy measurements of this regimen (response rate [RR], time to 
progression [TTP], and overall survival [OS]) of nab -paclitaxel plus ramucirumab as 
second-line therapy for metastatic gastroesophageal cancer. 
• Further evaluate toxicities associated with this regimen in patients with metastatic 
gastroesophageal cancer. 
3. 
STUDY PATIENT POPULATION AND DISCONTINUATION 
3.1 
Inclusion Criteria 
Patients must meet the following criteria in order to be included in the research study: 
1. Histologically confirmed metastatic adenocarcinoma of the esophagus, GE junction, or 
stomach that is not responsive to standard therapies. 
2. Measurable disease as measured by Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria Version 1.1 (Appendix E). 
3. Patients must have progressed on one prior line of chemotherapy in the metastatic setting 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 20 of 65 
 
• Patients will be allowed to have had previous neoadjuvant and/or adjuvant 
chemotherapy or chemoradiation therapy as long as treatment was completed > 6 
months prior to diagnosis of metastatic disease.  The neoadjuvant or adjuvant 
therapy in this setting will not be counted as a line of therapy in the metastatic or 
advanced setting. 
• Patients who develop metastatic disease or worsening of localized disease within 
6 months of the completion of neoadjuvant or adjuvant therapy will have the 
neoadjuvant or adjuvant therapy count as one line of therapy in the advanced 
setting.   
• Previous radiation therapy alone or in combination with single agent 
fluoropyrimidine (5-FU, capecitabine) in the localized or palliative setting will 
not count as a line of therapy. 
4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 
(Appendix A). 
5. Adequate hematologic function defined as: 
- Absolute neutrophil count (ANC) ≥1500/mm3 
- Hemoglobin (Hgb) >9 g/dL 
- Platelets >100,000/mm3 
6. Adequate liver function defined as: 
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the 
upper limit of normal (ULN)  
- Alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is 
present in the absence of liver metastasis 
- Total bilirubin ≤1.5 x ULN (unless the patient has Grade 1 bilirubin elevation due 
to Gilbert’s disease or a similar syndrome involving slow conjugation of 
bilirubin) 
7. Adequate renal function defined as serum creatinine ≤1.5 mg/dL (133 μmol/L) OR 
calculated creatinine clearance >40 mL/min as calculated by Cockcroft and Gault 
Formula. 
8. Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer 
Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03) 
9. Women of childbearing potential must have a negative serum or urine pregnancy test 
performed ≤7 days prior to start of treatment.  If a woman becomes pregnant or suspects 
she is pregnant while participating in this study, she must agree to inform her treating 
physician immediately. 
10. Male patients with female partners of childbearing potential and women patients of 
childbearing potential are required to use two forms of acceptable contraception, 
including one barrier method, during their participation in the study and for 6 months 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 21 of 65 
 
following last dose of study drug(s).  Male patients must also refrain from donating 
sperm during their participation in the study (Appendix C). 
11. Life expectancy >3 months. 
12. Age ≥18 years. 
13. Willingness and ability to comply with study and follow-up procedures. 
14. Ability to understand the nature of this study and give written informed consent. 
3.2 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from study entry: 
1. Patients who have received any other investigational agents, chemotherapy, biologic 
therapy, or radiation therapy within the 28 days prior to day 1 of the study.  For 
investigational, chemotherapy, or biologic therapy, patients will be allowed on study if 5 
half- lives or greater have elapsed since last dose of drug or 28 days, whichever is shorter.   
2. History of other carcinomas (in situ and invasive) within the last five years that, in the 
investigator’s opinion, may affect interpretation of the endpoints of this study. 
3. Patients with other concurrent severe and/or uncontrolled medical disease which could 
compromise safety of treatment as so judged by treating physician (i.e., severely impaired 
lung function, severe infection, ventricular arrhythmias active ischemic heart disease, 
known active vasculitis of any cause, chronic liver or renal disease). 
4. Patients with prior taxane chemotherapy. 
5. A known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis 
B infection, or other serious chronic infection requiring ongoing intravenous treatment. 
6. Women who are pregnant or breast-feeding 
7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
or psychiatric illness/social situations that would limit safety or compliance with study 
requirements or may interfere with the interpretation of the results. 
8. Inadequately controlled hypertension (blood pressure>150 systolic and/or diastolic >100 
mmHg) (patients with values above these levels must have their blood pressure (BP) 
controlled with medication prior to starting treatment). 
9. Any of the following cardiac diseases currently or within the last 6 months: 
- Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple 
Gated Acquisition (MUGA) scan or echocardiogram (ECHO) 
- QTc interval >480 ms on screening electrocardiogram (ECG) per institutional 
standard 
- Unstable angina pectoris 
- Congestive heart failure (New York Heart Association (NYHA) ≥ Grade 2 
[Appendix B]) 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 22 of 65 
 
- Acute myocardial infarction 
- Clinically significant conduction abnormality not controlled with pacemaker or 
medication 
- Significant ventricular or supraventricular arrhythmias (patients with chronic rate-
controlled atrial fibrillation in the absence of other cardiac abnormalities are 
eligible) 
- Valvular disease with significant compromise in cardiac function 
10. History of hypertensive crisis or hypertensive encephalopathy. 
11. History of stroke or transient ischemic attack (TIA) within the past 6 months. 
12. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent 
peripheral arterial thrombosis) within 6 months prior to initiation of therapy. 
13. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess 
within the past 6 months. 
14. Patients may not have received other agents, either investigational or marketed, which act 
by primary anti-angiogenic mechanisms.  
15. Major surgical procedure, open biopsy; or significant traumatic injury within 28 days 
prior to study initiation, or anticipation of need for major surgical procedure during the 
course of the study. 
16. Core biopsy or other minor surgical procedure, excluding placement of a vascular access 
device, within 7 days prior to initiation of therapy. 
17. Patients with proteinuria, as demonstrated by a Urine Protein on dipstick of 2+ or greater 
at screening. 
18. Any non-healing wound, ulcer, or bone fracture. 
19. Any clinical evidence or history of a bleeding diathesis or significant coagulopathy (in 
the absence of therapeutic anticoagulation). 
20. Therapeutic anticoagulation with coumarin-derivatives will not be permitted.  However, a 
maximum daily dose of 1 mg will be permitted for port line patency.  Anticoagulation 
with low molecular weight heparin or anti-Factor Xa agents will be allowed. 
21. History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month 
prior to initiation of therapy. 
3.3 
Discontinuation from Study Treatment 
Patients will be discontinued from study treatment for any of the following reasons: 
• 
Disease progression 
• 
Irreversible or intolerable toxicity or abnormal laboratory values thought to be related to 
drug toxicity 
• 
Conditions requiring therapeutic intervention not permitted by the protocol 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 23 of 65 
 
• 
Intercurrent illness (this will be at the investigator’s discretion) 
• 
Inability of the patient to comply with study requirements 
• 
Patient requests to discontinue treatment 
• 
Patient withdraws consent from the study  
• 
Non-compliance/lost to follow-up 
• 
Pregnancy 
After discontinuation from protocol treatment, patients must be followed for adverse events 
(AEs) for 30 days after their last dose of study drug.  All new AEs occurring during this period 
must be reported and followed until resolution, unless, in the opinion of the investigator, these 
values are not likely to improve, because of the underlying disease.  In this case, the investigators 
must record his or her reasoning for this decision in the patients’ medical records and as a 
comment in the electronic Case Report Form (eCRF). 
All patients who have Grade 3 or 4 laboratory abnormalities (per NCI CTCAE v 4.03) at the time 
of discontinuation must be followed until the laboratory values have returned to Grade 1 or 2, 
unless it is, in the opinion of the investigator, not likely that these values are to improve.  In this 
case, the investigator must record his or her reasoning for making this decision in the patients’ 
medical records and as a comment in the eCRF. 
4. 
STUDY REGISTRATION 
Registration must occur prior to the initiation of protocol therapy.  Patients eligible to participate 
in the study may be enrolled through the SCRI Innovations Central Enrollment Desk.  Patient 
registration will be confirmed via email within 24 hours, or by the next business day. 
5. 
STUDY DESIGN 
This is a Phase II, open-label, non-randomized study.  Patients will be given nab-paclitaxel by IV 
at a dose of 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle (weekly for 3 weeks with 1 week 
of rest) in combination with ramucirumab 8 mg/kg IV on Days 1 and 15.  Restaging will occur 
every 2 cycles (8 weeks), and patients with an objective response or stable disease (SD) will 
remain on study until evidence of progressive disease, unacceptable toxicity, or study 
termination.   
The planned enrollment for this study is 65 patients.   
The study schema is presented in Figure 2. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 24 of 65 
 
 
Figure 2 
Study Schema 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 25 of 65 
 
5.1 
Treatment Plan 
5.1.1 
Nab-paclitaxel 
Nab-paclitaxel 
 
IV on D1, D8, and D15  
All patients entering this study will receive 125 mg/m2 of nab-paclitaxel by IV per institutional 
standard on Days 1, 8, and 15 of each 28-day cycle.  Nab-paclitaxel will be given prior to 
ramucirumab infusion. 
5.1.2 
Ramucirumab 
All patients entering this study will receive 8 mg/kg of ramucirumab by IV per institutional 
standard on Days 1 and 15 of each 28-day cycle. 
Premedication is recommended prior to infusion of ramucirumab.  The recommended 
premedication agents include H1 antagonists such as diphenhydramine hydrochloride (or 
equivalent) 25-50 mg PO or IV given 15-30 minutes prior to start of infusion.  Additional 
premedication may be provided at investigator discretion.  Premedication must be provided in 
the setting of a prior Grade 1-2 infusion-related reaction, as detailed in Section 6.2.2.1.  All 
premedication administered must be adequately documented in the eCRF. 
5.2 
Treatment Duration 
Patients will be evaluated for toxicity at the start of each cycle.  Every 2 cycles, restaging will 
occur with imaging and laboratory chemistries as defined in Appendix D.  Patients will continue 
on treatment until progression as defined in Appendix E or intolerance to side effects.   
5.3 
Concomitant Medications 
Patients will be instructed not to take any additional medications during the course of the study 
without prior consultation with the research team.  At each visit, the patient will be asked about 
any new medications he/she is taking or has taken after the start of the study drug. 
5.3.1 
Permitted Concomitant Medications 
Premedication with anti-emetics is allowed according to standard practice guidelines. 
Medications may be administered for maintenance of existing conditions prior to study 
enrolment or for a new condition that develops while on study, including but not limited to the 
following: 
• Therapeutic anticoagulation with coumarin-derivatives will not be permitted.  However, a 
maximum daily dose of 1 mg will be permitted for port line patency.  Should a 
thrombotic event occur while the patient is receiving treatment, the patient may continue 
on protocol treatment, but low molecular weight heparin will be the preferred treatment  
• The use of granulocyte colony-stimulating factor (G-CSF) is permitted during 
investigational therapy at the discretion of the investigator, in accordance with ASCO 
guidelines (Smith et al. 2006).  G-CSF or similar agents are strongly recommended 
following Grade 3 or 4 neutropenia of duration >5 days or following any incidence of 
febrile neutropenia (ANC <1.0 x 103/μL [1.0 x 109/L] with a single temperature ≥38.3°C 
or a sustained temperature of ≥38.0°C for more than 1 hour). 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 26 of 65 
 
• The use of erythroid-stimulating factors (for example, erythropoietin) is permitted at the 
discretion of the investigator consistent with institutional guidelines. 
Other medications considered necessary for the patient’s safety and well-being may be given at 
the discretion of the investigator with the exception of those listed in Section 5.3.2. 
5.3.2 
Prohibited Concomitant Medications 
The following treatments are prohibited while in this study: 
• No other investigational therapy should be given to patients.  No anticancer agents other 
than the study medications should be given to patients.  If such agents are required for a 
patient, then the patient must first be withdrawn from the study. 
• Anticoagulation with coumarin-derivatives will not be permitted.  However, a maximum 
daily dose of 1 mg will be permitted for port line patency.   
• Herbal preparations/medications are not allowed throughout the study.  These herbal 
medications include, but are not limited to: St. John’s wort, kava, ephedra (ma huang), 
gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.  
Patients should stop using these herbal medications 7 days prior to first dose of study drug. 
6. 
DOSE MODIFICATIONS 
Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts 
or maximum non-hematologic toxicity from the preceding cycle of therapy.  Treatment may be 
delayed to allow sufficient time for recovery.  If dose modification below dose level -1 is 
required in a patient receiving benefit, the schedule of one or both drugs may be modified with 
approval of the Study Chair. 
If the investigator believes the toxicity to be due to only one of the study agents, that agent may 
be held and/or dose reduced and treatment with the other agent may continue. 
All dose reductions will be made from the planned dosages, with a maximum allowable 
treatment delay of 3 weeks during chemotherapy.  If toxicity remains unresolved, the patient will 
discontinue the offending study agent and treatment with the other agent may continue.  Patients 
should be evaluated weekly (at a minimum), if therapy is on hold. 
The dose level reductions to be used in this study are shown in Table 1.  No dose re-escalation is 
allowed. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 27 of 65 
 
Table 1 
Dose Level Modifications 
Dose Level 
Nab-paclitaxel 
Ramucirumab 
Starting Dose  
125 mg/m2 
8 mg/kg 
Dose Level -1 
100 mg/m2 
6 mg/kg 
Dose Level -2 
75 mg/m2 
5 mg/kg 
 
6.1 
Dose Modifications Due to Hematologic Toxicity 
6.1.1 
Administration of Nab-Paclitaxel to Patients with Abnormal Hematologic 
Function 
Nab-paclitaxel dosing should not be administered at the start of each cycle until the ANC returns 
to ≥1.5 x 109 cells/L and the platelet count returns to ≥100 x 109 cells/L.  For patients receiving 
weekly nab-paclitaxel, for each subsequent dose of nab-paclitaxel within a cycle (Days 8 and 
15), patients must have an ANC ≥1.0 x 109 cells/L and platelets >75 x 109 cells/L.  If the ANC 
and platelets are not adequate for treatment on Day 8 and/or 15, the dose will be omitted, but the 
total cycle length will remain the same. 
6.1.2 
Dose Reductions and Guidelines for Optional use of Growth Factors for 
Hematologic Toxicity 
Prophylactic G-CSF use is not permitted during Cycle 1.  Table 2 provides a guideline for 
implementing dose reductions and optional use of growth factor treatment for hematologic 
toxicity. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 28 of 65 
 
Table 2 
Use of G-CSF and Nab-paclitaxel Dose Reductions for Hematologic Toxicity 
Adverse Event 
Occurrence 
Action to be Taken 
ANC <0.5 x 109 cells/L (nadir count) 
with neutropenic fever >100.4°F 
OR 
Delay of next cycle due to persistent 
neutropenia (ANC <1.5 x 109 cells/L) 
OR 
For patients on weekly treatment 
whose next treatment within the cycle 
(Day 8 or Day 15) is omitted due to 
persistent neutropenia (ANC 
<1.0 x 109 cells/L) 
OR 
Neutropenia <0.5 x 109 cells/L for >1 
week 
Any 
Occurrence 
At the first occurrence of a hematological 
toxicity (as outlined in the Adverse Event 
column), the same dose is maintained and G-
CSF is given as outlined below.  In the event 
that a hematological toxicity re-occurs in the 
face of G-CSF, dose reduction to the next 
lower level for every protocol treatment will 
be required for subsequent cycles once ANC 
is 1.5 x 109 cells/L 
 
If G-CSF is given concurrently with weekly 
nab-paclitaxel, administration may begin the 
day after nab-paclitaxel is given and should 
stop at least 48 hours prior to when nab-
paclitaxel is given the following week. 
Thrombocytopenia Grade 3 or Grade 
4* 
1st 
Occurrence 
Dose reduction to next lower level 
Recurrence 
Dose reduction to next lower level** 
*See the National Cancer Institute Toxicity Criteria Scale for the definitions of Grade 3 and Grade 4 events. 
**If dose modification below dose level -1 is required in a patient receiving benefit, the schedule of one or both drugs may be 
modified with approval of the Study Chair. 
G-CSF Administration 
For weekly nab-paclitaxel administration, administer G-CSF 5 mcg/kg/day (rounded to the 
nearest vial size per investigator/institution’s standard of care) 24 hours after chemotherapy and 
hold 48 hours prior to the next dose. 
6.2 
Dose Modifications Due to Non-Hematologic Toxicity 
Dose modifications for non-hematologic toxicities for nab-paclitaxel and ramucirumab are 
addressed in this section. 
6.2.1 
Nab-Paclitaxel Non-Hematologic Dose Modifications 
6.2.1.1 
Administration of Nab-Paclitaxel to Patients with Abnormal Hepatic Function 
Nab-paclitaxel should only be administered if hepatic function is within the parameters 
established in the eligibility criteria.  Hepatic toxicity from taxanes may occur, but it is 
uncommon.  Therefore, hepatic dysfunction that occurs while the patient is on study should 
prompt an evaluation to determine the cause, including the possibility of progressive metastatic 
disease and hepatotoxicity from concurrent medications. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 29 of 65 
 
6.2.1.2 
Sensory Neuropathy 
Nab-paclitaxel should be withheld in patients who experience ≥ Grade 3 sensory neuropathy.  
Treatment may be resumed at the next lower dose level (see Table 1) in subsequent cycles after 
the sensory neuropathy improves to ≤ Grade 1.  The time to resolution to ≤ Grade 1 should be the 
AE duration used for AE reporting.  In those patients who experience Grade 4 sensory 
neuropathy, study drug should be withheld, and treatment resumed at a reduction of 2 dose levels 
(Dose Level -2; see Table 1) in subsequent cycles after the sensory neuropathy improves to 
≤ Grade 1.  Note: the investigator may elect to dose modify for Grade 3 sensory neuropathy. 
6.2.1.3 
Hypersensitivity Reactions 
Hypersensitivity reactions rarely occur with nab-paclitaxel.  If they do occur, minor symptoms 
such as flushing, skin reactions, dyspnea, lower back pain, hypotension, or tachycardia may 
require temporary interruption of the infusion.  Patients with mild or moderate reactions may be 
premedicated per institutional standard and may continue treatment.  However, severe reactions, 
such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema or 
generalized urticaria require immediate discontinuation of nab-paclitaxel administration and 
aggressive symptomatic therapy.  Patients who experience a severe hypersensitivity reaction to 
nab-paclitaxel should not be re-challenged.  It is not recommended to administer nab-paclitaxel 
to patients with prior hypersensitivity to a taxane.  
6.2.2 
Ramucirumab Non-Hematologic Toxicity 
6.2.2.1 
Infusion Related Reactions 
As with other monoclonal antibodies, infusion-related reactions may occur during or following 
ramucirumab administration.  Patients should be closely monitored for signs and symptoms 
indicative of an infusion-related reaction starting with the initiation of the infusion until at least 
1 hour after the end of the infusion in an area where resuscitation equipment and other agents 
(e.g., epinephrine, corticosteroids) are readily available. 
The following are treatment guidelines for infusion-related reactions: 
Grade 1 
• Slow the infusion rate by 50%. 
• Monitor the patient for worsening of condition. 
• After symptoms resolve, medication may resume at previous rate per investigator’s 
discretion. 
• For subsequent infusions, premedicate with diphenhydramine hydrochloride 50 mg IV 
(or equivalent); additional premedication may be administered at the investigator’s 
discretion. 
Grade 2 
• Stop the infusion. 
• Administer diphenhydramine hydrochloride 50 mg IV (or equivalent), acetaminophen 
650 mg orally for fever, and oxygen 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 30 of 65 
 
• Resume the infusion at 50% of the prior rate once the infusion-related reaction has 
resolved or decreased to Grade 1; the infusion duration should not exceed 2 hours. 
• Monitor for worsening of condition. 
• For subsequent infusions, premedicate with diphenhydramine hydrochloride 50 mg IV 
(or equivalent); additional premedication may be administered at the investigator’s 
discretion. 
For a second Grade 1 or 2 infusion-related reaction, administer dexamethasone 8 to 10 mg IV (or 
equivalent); then, for subsequent infusions, premedicate with diphenhydramine hydrochloride 
50 mg IV (or equivalent), acetaminophen 650 mg orally, and dexamethasone 8 to 10 mg IV (or 
equivalent). 
Grade 3 
• Stop the infusion and disconnect the infusion tubing from the patient. 
• Administer diphenhydramine hydrochloride 50 mg IV (or equivalent), dexamethasone 8 
to 10 mg IV (or equivalent), bronchodilators for bronchospasm, and other 
medications/treatment as medically indicated. 
• Patients who have a Grade 3 infusion-related reaction will not receive further 
ramucirumab, but will continue on nab-paclitaxel. 
Grade 4 
• Stop the infusion and disconnect the infusion tubing from the patient. 
• Administer diphenhydramine hydrochloride 50 mg IV (or equivalent), dexamethasone 8 
to 10 mg IV (or equivalent), and other medications/treatment as medically indicated. 
• Give epinephrine or bronchodilators as indicated. 
• Hospital admission for observation may be indicated. 
• Patients who have a Grade 4 infusion-related reaction will not receive further 
ramucirumab, but will continue to be followed on on nab-paclitaxel. 
6.2.2.2 
Hypertension 
The following are treatment guidelines for hypertension that develops during the study: 
Grade <3 
• If the hypertension is not associated with symptoms, continue ramucirumab and initiate 
antihypertensive therapy. 
• If the hypertension is associated with symptoms, hold ramucirumab until symptoms 
resolve and initiate antihypertensive therapy. 
• If ramucirumab is held for hypertension (that is, symptomatic hypertension, markedly 
elevated blood pressure unresponsive to antihypertensive therapy), the dose of 
ramucirumab should be reduced upon re-treatment (resolution to Grade 1) to 6 mg/kg 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 31 of 65 
 
every 2 weeks.  A second dose reduction to 5 mg/kg every 2 weeks should be undertaken 
if an additional postponement of ramucirumab is required. 
Grade 3 (systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg; medical intervention indicated; 
more than 1 drug or more intensive therapy than previously used indicated). 
• For Grade 3 hypertension not associated with symptoms, continue ramucirumab with 
more intensive antihypertensive therapy.  If systolic BP remains ≥160 mm Hg or diastolic 
BP ≥100 mm Hg >2 weeks after initiation of additional antihypertensive therapy, hold 
ramucirumab while continuing appropriate antihypertensive therapy (resolution to Grade 
1). 
• If the hypertension is associated with symptoms, hold ramucirumab until symptoms 
resolve and initiate antihypertensive therapy. 
• If ramucirumab is held for hypertension (that is, symptomatic hypertension, markedly 
elevated blood pressure unresponsive to antihypertensive therapy), the dose of 
ramucirumab should be reduced upon re-treatment to 6 mg/kg every 2 weeks.  A second 
dose reduction to 5 mg/kg every 2 weeks should be undertaken if an additional 
postponement of ramucirumab is required. 
Grade 4 or refractory 
• Patients with Grade 4 hypertension (life-threatening consequences; for example, 
malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis; or 
urgent intervention indicated) or patients whose hypertension is poorly controlled 
(>160 mm Hg systolic or >100 mm Hg diastolic for >4 weeks) despite appropriate oral 
medication (>2 oral agents at maximum tolerated dose) will be discontinued from 
ramucirumab.   
6.2.2.3 
Proteinuria 
If, while on ramucirumab therapy, a patient has proteinuria ≥2+ per a dipstick or routine 
urinalysis, ramucirumab therapy will continue as scheduled, and a 24-hour urine collection will 
be conducted prior to the subsequent scheduled treatment cycle.  If the protein level is <2 g/24 
hours, the patient will continue on ramucirumab therapy at the same dose without interruption.  
If the protein level is ≥2 g/24 hours, hold ramucirumab therapy for that treatment and a 24-hour 
urine collection will be repeated.  Ramucirumab treatment will resume at 6 mg/kg once the 
protein level returns to <2 g/24 hours.  A second dose reduction of ramucirumab to 5 mg/kg is 
permitted if proteinuria ≥2 g/24 hours recurs.  The patient will be discontinued from 
ramucirumab treatment if the protein level is >3 g/24 hours, if there is a third occurrence of 
proteinuria ≥2 g/24 hours, or if the protein level does not return to <2 g/24 hours within 3 weeks. 
6.2.2.4 
Thromboembolic Events 
Ramucirumab therapy should be discontinued in the event of any Grade 3/4 ATE or any 
Grade 3/4 venous thromboembolism that is considered by the investigator to be life-threatening, 
or symptomatic and not adequately treated by anticoagulation therapy.  Ramucirumab therapy 
may be continued in the setting of an incidentally diagnosed, asymptomatic deep vein thrombosis 
or pulmonary embolism, or following a symptomatic deep vein thrombosis or pulmonary 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 32 of 65 
 
embolism when symptoms have resolved with the institution of anticoagulation therapy.  
Ramucirumab should also be discontinued in the setting of a deep vein thrombosis or pulmonary 
embolism that occurs or intensifies while the patient is receiving therapeutic anticoagulation 
therapy. 
6.2.2.5 
Other Ramucirumab Non-Hematological Toxicities 
The events in Table 3 are associated with ramucirumab or other antiangiogenic therapeutic 
agents. 
Table 3 
Other Ramucirumab Non-Hematological Toxicities 
Event 
Action to be taken 
Bleeding (hemorrhagic) event 
Grade 3 or 4 
 
Discontinue ramucirumab 
Gastrointestinal perforation 
Any grade 
 
Discontinue ramucirumab 
Fistula formation 
Any grade 
 
Discontinue ramucirumab 
Wound dehiscence  
(Requiring medical or surgical 
therapy) 
 
Discontinue ramucirumab 
Congestive heart failure (CHF) 
Grade 3 or 4  
 
Discontinue ramucirumab 
Reversible Posterior 
Leukoencephalopathy Syndrome 
(RPLS) 
Any grade (confirmed by MRI) 
 
 
Discontinue ramucirumab 
7. 
STUDY ASSESSMENTS AND EVALUATIONS 
7.1 
Overview 
All patients should visit the study center on the days specified within this protocol.  The 
complete Schedule of Assessments for this study is shown in Appendix D.  The baseline physical 
examination, medical history, ECOG performance status, complete blood counts (CBC), 
differential and platelets, complete metabolic profile (CMP) plus magnesium and phosphorous, 
urinalysis, prothrombin time (PT)/International Normalization Ratio (INR) and partial 
thromboplastin time (PTT) and ECG should be done ≤7 days prior to initiation of treatment.  
However, if these initial examinations are obtained within 72 hours of Cycle 1 Day 1 they do not 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 33 of 65 
 
have to be repeated.  A pregnancy test must be performed within 72 hours of Cycle 1 Day 1.  CT 
scans should be performed ≤8 weeks prior to initiation of treatment, as should the tumor marker, 
carcinoembryonic antigen (CEA).   
7.2 
Baseline Study Assessments 
The following information will be collected and procedures will be performed for each patient at 
screening: 
• Written informed consent prior to any other study-related procedures (≤28 days prior to 
initiation of treatment) 
• Medical history 
• Physical examination, measurements of height (first visit) and weight 
• Vital signs (resting heart rate, BP, respiratory rate, and oral temperature) 
• ECOG performance status (see Appendix A) 
• 12-lead ECG 
• Concomitant medication review 
• CBC (complete blood count) including Hgb, hematocrit, white blood cell count with 3-
part differential and platelets 
• CMP to include: glucose, blood urea nitrogen (BUN), creatinine, sodium, potassium, 
chloride, calcium, carbon dioxide (CO2), alkaline phosphatase (ALP), AST, ALT, total 
bilirubin, total protein, and albumin plus magnesium and phosphorous. 
• Coagulation analysis:  PT/PTT/INR (at baseline and then as clinically indicated) 
• Urine dipstick  
• Serum or urine pregnancy test (must be performed within 72 hours of Cycle 1 Day 1) 
• CEA tumor marker ≤ 8 weeks prior to initiation of study treatment 
• CT scans of the chest, abdomen/pelvis ≤ 8 weeks prior to initiation of study treatment.  
CT scans of abdomen/pelvis are preferred but CT scans of the abdomen will be accepted. 
7.3 
Study Treatment Assessments  
7.3.1 
Day 1 of each cycle (+/- 72 hours) 
• Update of medical history 
• Physical examination, including measurement of weight 
• Vital signs 
• ECOG performance status 
• Adverse event (AE) assessment 
• Concomitant medication review 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 34 of 65 
 
• CBC, including 3-part differential and platelets  
• CMP plus magnesium and phosphorous  
• Urine dipstick  
7.3.2 
Day 8 and 15 of each cycle  
• AE assessment 
• CBC, including 3-part differential and platelets 
• Urine dipstick (Day 15 only) 
7.4 
Response Assessment Every 2 Cycles  
Patients will be evaluated for response to treatment after every 2 cycles of treatment, at the End 
of Treatment Visit and in follow-up prior to disease progression.  The following assessments will 
be performed:  
• CT scans of chest, abdomen and pelvis  
• CEA tumor marker 
Patients with progressive disease or unacceptable toxicity should be discontinued from the study 
unless the patient is receiving clinical benefit and the Study Chair has approved patient to stay on 
study; patients with SD or response to therapy will continue treatment. 
7.5 
End-of-Study Treatment   
The follow-up evaluations required after treatment ends due to disease progression or once the 
patient is discontinued due to unacceptable toxicity or decision to discontinue treatment by the 
patient or the study physician are specified in Appendix D. 
After withdrawal from or completion of protocol treatment, patients must be followed for AEs 
for 30 calendar days (+3) after the last dose of study drug.  The following assessments will be 
performed: 
• Update of medical history 
• Physical examination, including measurement of weight 
• Vital signs 
• ECOG performance status 
• AE assessment 
• Concomitant medication review 
• CBC, including 3-part differential and platelets 
• CMP plus magnesium and phosphorous 
• Urine dipstick  
• CT scans of chest, abdomen and pelvis (if not done in the previous 8 weeks) 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 35 of 65 
 
• CEA tumor marker 
 
7.6 
Follow-up 
7.6.1 
Follow-up for Patients Who Discontinue Prior to Disease Progression 
Patients discontinuing treatment for any reason other than progressive disease (PD) will be 
monitored for evidence of disease progression.  Patients will be followed every 3 months for up 
to 12 months after the last patient has been enrolled on study.  Assessments at these visits will be 
performed as described in Appendix D.   
7.6.2 
Survival Follow-Up 
Survival will be assessed in all patients at 6 and 12 months after the last patient has been enrolled 
on the study.  Patients may be contacted during outpatient visits or by telephone.  After 12 
months no additional follow-up will be required. 
8. 
DRUG FORMULATION, AVAILABILITY, ADMINISTRATION, AND 
TOXICITY INFORMATION 
8.1 
Nab-Paclitaxel 
 
Investigational Product 
Dosage Form and Strength 
Manufacturer 
Nab-paclitaxel 
100 mg 
Celgene Corporation 
 
8.1.1 
Labeling, Packaging, and Supply 
Nab-paclitaxel will be supplied by Celgene. 
The immediate packaging will contain a statement to conform with FDA Investigational New 
Drug (IND) requirements as follows: Caution: New Drug - Limited by Federal (or United States) 
law to investigational use. 
All study drugs must be kept in a secure place under appropriate storage conditions.  Storage 
conditions for nab-paclitaxel are included on the investigational product label. 
The SCRI Innovations must be granted access on reasonable request to check drug storage, 
dispensing procedures, and accountability records. 
8.1.2 
Preparation and Administration of Nab-paclitaxel 
Nab-paclitaxel is prepared and administered as an IV infusion per institutional standard. 
No premedication to prevent hypersensitivity reactions is required prior to administration of nab-
paclitaxel.  However, if a mild or moderate hypersensitivity reaction occurs, the patient may be 
premedicated per institutional standard. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 36 of 65 
 
Additional information can be found in the prescribing information for nab-paclitaxel.   
8.1.3 
Precautions and Risks Associated with Nab-paclitaxel 
Precautions and risks are located in the IB. 
8.2 
Ramucirumab 
Ramucirumab is to be administered in accordance with the terms of its marketing authorization 
and in accordance with institutional standard of practice.  Please refer to the US Package Insert 
(USPI) for detailed information on how to prepare and administer ramucirumab. 
8.2.1 
Labeling, Packaging, and Supply 
Each site will procure a supply of ramucirumab, which is commercially available. 
All study drugs must be kept in a secure place under appropriate storage conditions.  Storage 
conditions for ramucirumab can be found in the USPI. 
SCRI Innovations must be granted access on reasonable request to check drug storage, 
dispensing procedures, and accountability records. 
8.2.2 
Preparation and Administration of Ramucirumab 
Ramucirumab is to be prepared and administered over 60 minutes and in accordance with  
institutional standard.   
8.2.3 
Precautions and Risks Associated with Ramucirumab 
Please refer to the USPI for detailed information on the risks associated with the use of 
ramucirumab. 
8.3 
Accountability for All Study drugs 
The Principal Investigator (or designee) is responsible for accountability of all used and unused 
study drug supplies at the site. 
All study drug inventories must be made available for inspection by SCRI Innovations or its 
representatives and regulatory agency inspectors upon request. 
At the end of the study, all SCRI Innovations Drug Accountability Record Form(s) will be 
completed by the site and sent to the SCRI Innovations Regulatory Department.  Study drug 
supplies must not be destroyed unless prior approval has been granted by SCRI Innovations or its 
representative.  Please contact SCRI Innovations regarding disposal of any study drug. 
9. 
RESPONSE EVALUATIONS AND MEASUREMENTS 
Response and progression will be evaluated in this study using the Response Evaluation Criteria 
in Solid Tumors (RECIST) v1.1 (see Appendix E).  Lesions are either measurable or non-
measurable according to the criteria.  The term “evaluable” in reference to measurability will not 
be used, as it does not provide additional meaning or accuracy. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 37 of 65 
 
10. 
STATISTICAL CONSIDERATIONS 
10.1 
Statistical Design 
This is a Phase II, open-label, non-randomized study.  The study is designed to determine the 
PFS of nab-paclitaxel in combination with ramucirumab for patients as second-line therapy for 
metastatic gastroesophageal cancer. 
10.2 
Sample Size Considerations 
This study seeks to improve median PFS in this patient population.  The historical median PFS is 
2.8 months; we hypothesize that nab-paclitaxel plus ramucirumab will increase median PFS to 
5 months.  With a 2-sided alpha of 5% and 80% power, a total of 52 events (progressions or 
deaths) will need to be observed.  With an 18-month recruitment and 6 months follow-up, 
assuming 20% of patients recruited will be free from progression or death at the end of the study, 
65 patients will need to be recruited into the study in order to observe 52 events. 
10.3 
Analysis Populations 
The following analysis populations will be used: 
• Full Analysis Set is defined as all patients who are enrolled in the study. 
• Safety Analysis Set is defined as patients in the Full Analysis Set who have received at 
least one dose of study treatment. 
• Efficacy Analysis Set is defined as patients in the Full Analysis Set who have received at 
least one dose of study treatment and have a baseline tumor assessment. 
• Per Protocol Set is defined as patients in the Efficacy Analysis Set who received at least 
75% of their intended starting doses of both nab-paclitaxel and ramucirumab study 
treatment during Cycles 1 and 2, and who either have at least one post-baseline tumor 
assessment, or who discontinued the study prior to their first post-baseline tumor 
assessment due to death or objective disease progression.   
10.4 
Data Analysis 
Data will be summarized by using counts and percentages for discrete parameters, and by 
descriptive statistics (number of observations, mean, standard deviation, median, minimum and 
maximum) for continuous parameters.  Baseline data to be tabulated will include demographic 
features such as gender, age, and race, as well as disease specific characteristics.  The number 
and percentage of patients who complete the study or who withdraw for any reason will be 
presented. 
Descriptive statistics, including mean, median, standard deviations and ranges for all continuous 
measures will be tabulated and reported.  Percentages and frequencies for all categorical 
measures will also be presented.  Time to events endpoints will be reported using Kaplan-Meier 
estimates, with 95% confidence intervals (CI) for median time to event. 
All analyses will be performed using SAS version 9.3 or later. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 38 of 65 
 
10.4.1 
Demographics and Baseline Characteristics 
Demographic and baseline disease characteristics will be summarized.  Data to be tabulated will 
include demographic features such as age, sex and race, as well as disease-specific 
characteristics. 
The number and percentages of patients screened, randomized, treated, completed the 
treatment/study and withdrawn from treatment/study for any reasons will be presented. 
10.4.2 
Efficacy Analysis 
Response evaluation will be based on RECIST v1.1 criteria (Appendix E). 
Analyses of PFS, TTP, OS, ORR and Disease Control Rate (DCR) will be performed using the 
Efficacy Analysis Set. 
• PFS is defined as the time from the first day of study drug administration (Day 1) to 
objective disease progression as defined by the RECIST v1.1 criteria, or death on study 
from any cause.  Patients who are alive and free from disease progression will be 
censored at the date of last adequate tumor assessment.  If no adequate post-treatment 
tumor assessments were obtained for a patient, PFS will censored at Day 1.  PFS is the 
primary endpoint variable in this study. 
 
• TTP is defined as the time from the first day of study drug administration (Day 1) to 
objective disease progression as defined by the RECIST v1.1 criteria.  Patients who are 
alive and free from disease progression will be censored at the date of last adequate 
tumor assessment.  If no adequate post-treatment tumor assessments were obtained for a 
patient, TTP will censored at Day 1. 
 
• OS is defined as the time from the first day of study drug administration (Day 1) to death 
from any cause.  Patients who are alive will be censored at the date of last known alive. 
 
• ORR is defined as the proportion of patients with confirmed complete response (CR) or 
confirmed partial response (PR), i.e., two CRs and/or PRs at least 4 weeks apart, 
according to the RECIST v1.1 criteria. 
 
• DCR is defined as the proportion of patients with best response of confirmed CR, 
confirmed PR, or SD, according to the RECIST v1.1 criteria.  
 
o For ORR and DCR, patients without a post-baseline tumor assessment will be 
classified as not evaluable (NE) and considered as non-responders in the efficacy 
analyses. 
For PFS, TTP and OS, Kaplan-Meier curves will be generated and the median time to event and 
the associated 95% CI be provided. 
For ORR and DCR, the estimates and the associated 95% CI (based on the Wald normal 
approximation method) will be calculated. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 39 of 65 
 
Efficacy analyses will be repeated on each of the efficacy endpoint variables (PFS, TTP, OS, 
ORR, and DCR) using the Per Protocol Set. 
10.4.3 
Safety Analysis 
Safety analyses will be performed for all patients in the Safety Analysis Set. 
Safety (discussed in Section 11) will be assessed through the analysis of the reported incidence 
of adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs (SAEs), AEs leading to 
treatment discontinuation, events of at least CTCAE Version 4.03 Grade 3 in severity, and AEs 
related to study treatment.  Laboratory data and other safety data will be summarized as 
appropriate.  A copy of CTCAE scoring system may be downloaded from: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. 
The AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA), and 
summarized using system organ class and preferred term.  In addition, summaries of TEAEs, 
SAEs, AEs leading to treatment discontinuation, AEs by maximum NCI CTCAE grade, and AEs 
related to study treatment will also be presented. 
Laboratory results (observed values and changed from baseline) will be listed and summarized 
by visit.  CTCAE grades will be applied to laboratory parameters where applicable.  Summaries 
of NCI CTCAE Version 4.03 grading and shifts from baseline will be tabulated as appropriate. 
Vital signs parameters (observed values and change from baseline) will be listed and 
summarized by visit.  
ECG and ECOG performance status findings will be listed and summarized by visit. 
10.5 
Analysis Time Points 
10.5.1 
Final Analysis 
The final analysis of the study will occur when a total of at least 52 PFS events have been 
observed. 
10.5.2 
Safety Review 
There are no scheduled interim safety reviews planned for this study. 
10.5.3 
Efficacy Review 
There are no scheduled interim efficacy analyses planned for this study. 
11. 
SAFETY REPORTING AND ANALYSES 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs, 
measurement of protocol-specified hematology, clinical chemistry, and other protocol-specified 
tests that are deemed critical to the safety evaluation of the study drug. 
The Principal Investigator is responsible for recognizing and reporting AEs to the SCRI 
Innovations Safety Department (SD) (see Section 11.1.5).  It is SCRI Innovations responsibility 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 40 of 65 
 
to report relevant SAEs to the applicable local or national regulatory bodies.  In addition, 
Investigators must report SAEs and follow-up information to their responsible Institutional 
Review Board (IRB) according to the policies of that IRB.  
The Principal Investigator is also responsible for ensuring that every staff member involved in 
the study is familiar with the content of this section. 
11.1 
Definitions   
11.1.1 
Adverse Events 
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related.  An AE (also known as adverse experience) can 
be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or 
disease temporarily associated with the use of a drug, without any judgement about causality.  
An AE can arise with any use of the drug (e.g., off-label use, use in combination with another 
drug) and with any route of administration, formulation, dose or including overdose. 
11.1.2 
Serious Adverse Event 
An AE or a suspected adverse reaction (SAR) is considered “serious” if it results in any of 
the following outcomes: 
• Death 
• A life-threatening AE 
• Inpatient hospitalization of at least 24-hours or prolongation of existing 
hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• A congenital anomaly/birth defect 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in hospitalization, or development of drug dependency or drug 
abuse.   
It is important to distinguish between “serious” and “severe” AEs, as the terms are not 
synonymous.  Severity is a measure of intensity; however, an AE of severe intensity need not 
necessarily be considered serious.  Seriousness serves as the guide for defining regulatory 
reporting obligations.  “Serious” is a regulatory definition and is based on patient/event outcome 
or action usually associated with events that pose a threat to a patient’s life or vital functions.  
For example, nausea which persists for several hours may be considered severe nausea, but may 
not be considered an SAE.  On the other hand, a stroke which results in only a limited degree of 
disability may be considered only a mild stroke, but would be considered an SAE.  Severity and 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 41 of 65 
 
seriousness should be independently assessed when recording AEs on the eCRF and SAEs on the 
SAE Report Form. 
11.1.3 
Adverse Reaction 
An adverse reaction (AR) means any AE caused by a drug.  Adverse reactions are a subset of all 
SARs where there is a reason to conclude that the drug caused the event. 
11.1.4 
Suspected Adverse Reaction 
Suspected adverse reaction (SAR) means any AE for which there is a reasonable possibility that 
the drug caused the AE.  Reasonable possibility means that there is evidence to suggest a causal 
relationship between the drug and the AE.  A SAR implies a lesser degree of certainty about 
causality than AR, which means any AE caused by a drug. 
11.1.5 
Recording and Reporting of Adverse Events 
Recording of Adverse Events 
All AEs of any patient during the course of the research study will be recorded in the eCRF, and 
the investigator will give his or her opinion as to the relationship of the AE to the study drug 
treatment (i.e., whether the event is related or unrelated to study drug administration). 
All AEs should be documented.  A description of the event, including its date of onset and 
resolution, whether it constitutes an SAE or not, any action taken (e.g., changes to study 
treatment), and outcome, should be provided, along with the investigator’s assessment of 
causality (i.e., the relationship to the study treatment[s]).  For an AE to be a suspected treatment-
related event, there should be at least a reasonable possibility of a causal relationship between the 
protocol treatment and the AE.  Adverse events will be graded according to the NCI CTCAE 
v4.03, and changes will be documented. 
If the AE is serious, it should be reported immediately to SCRI Innovations SD.  Other untoward 
events occurring in the framework of a clinical study are to be recorded as AEs (i.e., AEs that 
occur prior to assignment of study treatment that are related to a protocol-mandated intervention, 
including invasive procedures such as biopsies, medication washout, or no treatment run-in). 
Any clinically significant signs and symptoms; abnormal test findings; changes in physical 
examination; hypersensitivity; and other measurements that occur will be reported as an AE, and 
collected on the relevant eCRF screen. 
Test findings will be reported as an AE if: the test result requires an adjustment in the study 
drug(s) or discontinuation of treatment, and/ or test findings require additional testing or surgical 
intervention, a test result or finding is associated with accompanying symptoms, or a test result is 
considered to be an AE by the investigator. 
Reporting Period for Adverse Events 
All AEs regardless of seriousness or relationship to nab-paclitxel and ramucirumab treatment 
(called study treatment), spanning from the start of study treatment, until 30 calendar days after 
discontinuation or completion of study treatment as defined by the clinical study for that patient, 
are to be recorded on the corresponding screen(s) included in the eCRF.   

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 42 of 65 
 
All AEs resulting in discontinuation from the study should be followed until resolution or 
stabilization.  All new AEs occurring during this period must be reported and followed until 
resolution unless, in the opinion of the investigator, the AE or laboratory abnormality/ies are not 
likely to improve because of the underlying disease.  In this case, the investigators must record 
his or her reasoning for this decision in the patient’s medical record and as a comment on the 
eCRF screen.   
After 30 days of completion of protocol-specific treatment or discontinuation, only AEs, SAEs, 
or deaths assessed by the investigator as treatment related are to be reported. 
11.1.6 
Assessment of Adverse Events 
All AEs and SAEs whether volunteered by the patient, discovered by study personnel during 
questioning, or detected through physical examination, laboratory test, or other means will be 
reported appropriately.  Each reported AE or SAE will be described by its duration (i.e., start and 
end dates), regulatory seriousness criteria if applicable, suspected relationship to the study drug 
(see following guidance), and actions taken. 
To ensure consistency of AE and SAE causality assessments, investigators should apply the 
following general guideline: 
YES:  There is a plausible temporal relationship between the onset of the AE and 
administration of the study medication, and the AE cannot be readily explained by the 
patient’s clinical state, intercurrent illness, or concomitant therapies, and/or the AE 
follows a known pattern of response to the study drug, and/or the AE abates or resolves 
upon discontinuation of the study drug or dose reduction and, if applicable, reappears 
upon re-challenge. 
NO:  Evidence exists that the AE has an etiology other than the study drug (e.g., pre-
existing medical condition, underlying disease, intercurrent illness, or concomitant 
medication), and/or the AE has no plausible temporal relationship to study drug 
administration (e.g., cancer diagnosed 2 days after first dose of study drug). 
11.2 
Serious Adverse Event Reporting by Investigators 
Adverse events classified by the treating investigator as serious require expeditious handling and 
reporting to SCRI Innovations SD in order to comply with regulatory requirements.  
Determination of life-threatening or serious is based on the opinion of the study Investigator.   
Serious AEs may occur at any time from the start of study treatment through the 30 days after 
their last dose of study drug follow-up period after the last study treatment.  The SCRI 
Innovations SD must be notified of all SAEs, regardless of causality, within 24 hours of the 
first knowledge of the event by the treating physician or research personnel.   
To report a SAE, the SAE Report Form should be completed with the necessary information. 
The SAE report should be sent to SCRI Innovations SD via fax or e-mail using the using the 
following contact information (during both business and non-business hours): 
SCRI Innovations Safety Department 
Safety Dept. Fax #:      1-866-807-4325 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 43 of 65 
 
Safety Dept. Email:     CANN.SAE@SCRI-Innovations.com 
Transmission of the SAE report should be confirmed by the site personnel submitting the report, 
and a copy of the confirmation should be retained with the patient’s records. 
The initial report must be as complete as possible, including an assessment of the causal 
relationship between the event and the investigational product(s), if available.  Information not 
available at the time of the initial report (e.g., an end date for the AE or laboratory values 
received after the report) must be documented on a follow-up report.  A final report to document 
resolution of the SAE is required. 
Follow-up information for SAEs and information on non-serious AEs that become serious should 
also be reported to SCRI Innovations SD as soon as it is available; these reports should be 
submitted using the SCRI Innovations SAE Report Form.  The detailed SAE reporting process 
will be provided to the sites in the SAE reporting guidelines contained in the study reference 
manual. 
Investigators must report SAEs and follow-up information to their responsible IRB according to 
the policies of the responsible IRB. 
11.3 
Recording of Adverse Events and Serious Adverse Events 
11.3.1 
Diagnosis versus Signs and Symptoms 
All AEs should be recorded individually in the patient’s own words (verbatim) unless, in the 
opinion of the Principal Investigator or designated physician, the AEs constitute components of a 
recognized condition, disease, or syndrome.  In the latter case, the condition, disease, or 
syndrome should be named rather than each individual sign or symptom.  If a constellation of 
signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at 
the time of reporting, each individual event should be recorded as an AE or SAE as appropriate 
on the relevant form(s) (SAE Report Form and/or AE eCRF screen).  If a diagnosis is 
subsequently established, it should be reported as follow-up information is available.  If a 
diagnosis is determined subsequent to the reporting of the constellation of symptoms, the 
signs/symptoms should be updated to reflect the diagnosis. 
Progression of malignancy (including fatal outcomes), if documented by use of appropriate 
method (for example, as per RECIST criteria for solid tumors), should not be reported as an 
SAE. 
11.3.2 
Persistent or Recurrent Adverse Events 
A persistent AE is one that extends continuously, without resolution, between patient evaluation 
time points.  Such events should only be recorded once on the SAE Report Form and/or the AE 
eCRF screen.  If a persistent AE becomes more severe or lessens in severity, it should be 
recorded on a separate SAE Report Form and/or AE eCRF screen. 
A recurrent AE is one that occurs and resolves between patient evaluation time points, and 
subsequently recurs.  All recurrent AEs should be recorded on an SAE Report Form and/or AE 
eCRF screen. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 44 of 65 
 
11.3.3 
Abnormal Laboratory Values 
If an abnormal laboratory value or vital sign is associated with clinical signs and/or symptoms, 
the sign or symptom should be reported as an AE or SAE, and the associated laboratory value or 
vital sign should be considered additional information that must be collected on the relevant 
eCRF screen.  If the laboratory abnormality is a sign of a disease or syndrome, only the diagnosis 
needs to be recorded on the SAE Report Form or AE eCRF screen. 
Abnormal laboratory values will be reported as an AE if: the laboratory result requires an 
adjustment in the study drug(s) or discontinuation of treatment, and/ or laboratory findings 
require additional testing or surgical intervention, a laboratory result or finding is associated with 
accompanying symptoms, or a laboratory result is considered to be an AE by the investigator. 
11.3.4 
Deaths 
Deaths that occur during the protocol-specified AE reporting period that are attributed by the 
Investigator solely to progression of disease will be recorded on the “Study Discontinuation” 
eCRF screen and should not be reported as an SAE.  All other on study deaths, regardless of 
attribution, will be recorded on an SAE Report Form and expeditiously reported to the SCRI 
Innovations SD. 
When recording a SAE with an outcome of death, the event or condition that caused or 
contributed to the fatal outcome should be recorded as the single medical concept on the SAE 
Report Form and Adverse Event screen of the eCRF.  If the cause of death is unknown and 
cannot be ascertained at the time of reporting, record “Death NOS” on the eCRF Adverse Event 
screen.  During post-study survival follow-up, deaths attributed to progression of disease will be 
recorded only on the “After Progressive Disease Follow-Up” eCRF screen. 
11.3.5 
Hospitalization, Prolonged Hospitalization, or Surgery 
Any AE that results in hospitalization of ≥24 hours or prolongation of pre-existing 
hospitalization should be documented and reported as an SAE unless specifically instructed 
otherwise in this protocol.  There are some hospitalizations that do not require reporting as an 
SAE. 
Treatment within or admission to the following facilities is not considered to meet the criteria of 
“inpatient hospitalization” (although if any other SAE criteria are met, the event must still be 
treated as an SAE and immediately reported): 
• Emergency Department or Emergency Room 
• Outpatient or same-day surgery units 
• Observation or short-stay unit 
• Rehabilitation facility 
• Hospice or skilled nursing facility 
• Nursing homes, Custodial care or Respite care facility 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 45 of 65 
 
Hospitalization during the study for a pre-planned surgical or medical procedure (one which was 
planned prior to entry in the study and properly documented in the eCRF), does not require 
reporting as an SAE to the SCRI Innovations SD. 
11.3.6 
Pre-Existing Medical Conditions 
A pre-existing medical condition is one that is present at the start of the study.  Such conditions 
should be recorded on the General Medical History eCRF screen.  A pre-existing medical 
condition should be recorded as an AE or SAE only if the frequency, severity, or character of the 
condition worsens during the study.  When recording such events on an SAE Report Form and/or 
AE eCRF screen, it is important to convey the concept that the pre-existing condition has 
changed by including applicable descriptors. 
11.3.7 
New Cancers 
The development of a new primary cancer should be regarded as an AE and will generally meet 
at least one of the seriousness criteria (see Section 11.1.2).  New primary cancers are those that 
are not the primary reason for the administration of the study treatment and have developed after 
the inclusion of the patient into the study.  They do not include metastases of the original cancer.  
Symptoms of metastasis or the metastasis itself should not be reported as an AE/SAE, as they are 
considered to be disease progression. 
11.3.8 
Pregnancy, Abortion, Birth Defects/Congenital Anomalies 
If a patient becomes pregnant while enrolled in the study, a Pregnancy Form (a paper report 
form, not available within the eCRF) should be completed and faxed to the SCRI Innovations 
SD.  SCRI Innovations SD should be notified immediately, irrespective of whether or not it 
meets the criteria for expedited reporting.  Abortions (spontaneous, accidental, or therapeutic) 
must also be reported to SCRI Innovations SD. 
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, this must be reported to the SCRI Innovations SD immediately.  Every effort should 
be made to follow the pregnancy for the final pregnancy outcome. 
Congenital anomalies/birth defects always meet SAE criteria, and should therefore be 
expeditiously reported as an SAE, using the previously described process for SAE reporting.  A 
Pregnancy Form should also have been previously completed, and will need to be updated to 
reflect the outcome of the pregnancy.  All neonatal deaths that occur within 28 days of birth 
should be reported, without regard to causality, as SAEs. In addition, any infant death after 28 
days that the Investigator suspects is related to the in utero exposure to the IP should also be 
reported to Celgene Drug Safety immediately by facsimile, or other appropriate method, within 
24 hours of the Investigator’s knowledge of the event using the SAE Report Form, or approved 
equivalent form. 
11.4 
SCRI Innovations Safety Department Serious Adverse Event Reporting 
Requirements 
SCRI Innovations SD will forward SAE information to Celgene Corporation within 1 business 
day of SCRI Innovations Safety Department personnel becoming aware of the SAE. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 46 of 65 
 
SCRI Innovations SD will forward Pregnancy information to Celgene Corporation within 1 
business day on a Pregnancy Form and Follow-Up Pregnancy Form with more information when 
the outcome of pregnancy is known.   
SCRI Innovations SD is responsible for reporting relevant SAEs to the competent authority, 
other applicable regulatory authorities, and participating investigators, in accordance with 
International Conference on Harmonisation (ICH) guidelines, FDA regulations, and/or local 
regulatory requirements. 
Safety Reporting to Celgene Corporation: 
Safety reporting will be communicated to Celgene Corporation using the contact information 
below: 
Celgene Corporation 
Global Drug Safety and Risk Management 
Connell Corporate Park 
300 Connell Dr.  Suite 6000 
Berkeley Heights, NJ  07922 
Fax: (908) 673-9115 
E-mail: drugsafety@celgene.com 
Celgene Corporation Study number: AX-CL-OTHER-PI-004374 
SCRI Study number:  GI 201 
The Celgene Corporation study number and SCRI study number referenced above should appear 
on the fax cover page. 
11.4.1 
SCRI Innovations Safety Department Assessment of Unexpected 
SCRI Innovations is responsible for assessing an AE or SAR as “unexpected.” 
An AE or SAR is considered “unexpected” when the following conditions occur: 
• Event(s) is not mentioned in the IB (or current USPI) 
• Event(s) is not listed at the specificity or severity that has been observed 
• An event(s) is not consistent with the General Investigative Plan or in the current 
application 
• Includes AEs or SAR that may be anticipated from the pharmacological properties of the 
study drug, or that occur with members of the drug class, but that have previously been 
observed under investigation 
When applicable, an unexpected AE may also apply to an event that is not listed in the current 
USPI or an event that may be mentioned in the USPI, but differs from the event because of 
greater severity or specificity.    
Known as Suspected Unexpected Serious Adverse Reactions (SUSAR), these events suspected 
(by the Investigator or Sponsor) to be related to the study drug, are unexpected (not listed in the 
Investigator’s Brochure [IB] or USPI), and are serious (as defined by the protocol) and require 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 47 of 65 
 
expedient submission to relevant health authorities within 7 days (fatal or life-threatening event) 
or 15 days (all serious events), or as defined by law.  The term SUSAR is used primarily in the 
reporting of events to regulatory authorities. 
Expected AEs are those events that are listed or characterized in the USPI or current IB. 
11.4.2 
Sponsor Reporting for Clinical Studies Under an Investigational New Drug 
Application 
All written IND Safety Reports submitted to the FDA by the SCRI Innovations SD must also be 
faxed to pharmaceutical company that is supporting the study: 
Celgene Corporation 
Attn: Medical Affairs Operations 
Connell Corporate Park 
400 Connell Drive Suite 700 
Berkeley Heights, NJ  07922 
E-mail: drugsafety@celgene.com 
12. 
QUALITY ASSURANCE AND QUALITY CONTROL 
12.1 
Study Monitoring, Auditing, and Inspecting 
The investigator will permit study-related monitoring, quality audits, and inspections by SCRI 
Innovations or its representative(s), government regulatory authorities, and the IRB of all study-
related documents (e.g., source documents, regulatory documents, data collection instruments, 
case report forms).  The investigator will ensure the capability for inspections of applicable 
study-related facilities.  The investigator will ensure that the study monitor or any other 
compliance or Quality Assurance reviewer is given access to all study-related documents and 
study-related facilities. 
At SCRI Innovations discretion, Source Document may be performed on all data items or a 
percentage thereof. 
Participation as an investigator in this study implies the acceptance of potential inspection by 
government regulatory authorities, SCRI Innovations or its representative(s). 
13. 
ETHICAL, FINANCIAL, AND REGULATORY CONSIDERATIONS 
This research study will be conducted according to the standards of Good Clinical Practice 
outlined in the ICH E6 Tripartite Guideline and CFR Title 21 part 312, applicable government 
regulations, institutional research policies and procedures and any other local applicable 
regulatory requirement(s). 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 48 of 65 
 
13.1 
Institutional Review Board Approval 
The clinical study protocol, informed consent form (ICF), IB, available safety information, 
patient documents (e.g., study diary), patient recruitment procedures (e.g., advertisements), 
information about payments (i.e., Principal Investigator payments) and compensation available 
to the patients and documentation evidencing the Principal Investigator’s qualifications should 
be submitted to the IRB for ethical review and approval if required by local regulations, prior to 
the study start. 
The Principal Investigator/Sponsor and/or designee will follow all necessary regulations to 
ensure appropriate, initial, and on-going, IRB study review.  The Principal Investigator/Sponsor 
(as appropriate) must submit and, where necessary, obtain approval from the IRB for all 
subsequent protocol amendments and changes to the informed consent document.  Investigators 
will be advised by SCRI Innovations or designee whether an amendment is considered 
substantial or non-substantial and whether it requires submission for approval or notification 
only to an IRB. 
Safety updates for nab-paclitaxel, will be prepared by SCRI Innovations or its representative as 
required, for distribution to the Investigator(s) and submission to the relevant IRB. 
13.2 
Regulatory Approval 
As required by local regulations, SCRI Innovations will ensure all legal aspects are covered, and 
approval of the appropriate regulatory bodies obtained, prior to study initiation.  If required, 
SCRI Innovations will also ensure that the implementation of substantial amendments to the 
protocol and other relevant study documents happen only after approval by the relevant 
regulatory authorities. 
13.3 
Informed Consent 
Informed consent is a process by which a patient voluntarily confirms his or her willingness to 
participate in a particular study after having been informed of all aspects of the study that are 
relevant to the patient's decision to participate.  Informed consent is documented by means of a 
written, signed, and dated ICF. 
The ICF will be submitted for approval to the IRB that is responsible for review and approval of 
the study.  Each consent form must include all of the relevant elements currently required by the 
FDA, as well as local county authority or state regulations and national requirements. 
Before recruitment and enrollment into the study, each prospective candidate will be given a full 
explanation of the research study.  Once the essential information has been provided to the 
prospective candidate, and the Investigator is sure that the individual candidate understands the 
implications of participating in this research study, the candidate will be asked to give consent to 
participate in the study by signing an ICF.  A notation that written informed consent has been 
obtained will be made in the patient’s medical record.  A copy of the ICF, to include the patient’s 
signature, will be provided by the investigator to the patient. 
If an amendment to the protocol substantially alters the study design or the potential risks to the 
patients, the patient’s consent to continue participation in the study should be obtained. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 49 of 65 
 
13.3.1 
Confidentiality 
13.3.1.1 Patient Confidentiality 
Confidentiality of patient’s personal data will be protected in accordance with the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA), and national data protection 
laws, as applicable.  HIPAA regulations require that, in order to participate in the study, a patient 
must sign an authorization form for the study that he or she has been informed of following: 
• What protected health information (PHI) will be collected from patients in this study 
• Who will have access to that information and why 
• Who will use or disclose that information 
• That health information may be further disclosed by the recipients of the information, and 
that if the information is disclosed the information may no longer be protected by federal 
or state privacy laws 
• The information collected about the research study will be kept separate from the 
patient’s medical records, but the patient will be able to obtain the research records after 
the conclusion of the study 
• Whether the authorization contains an expiration date 
• The rights of a research patient to revoke his or her authorization 
In the event that a patient revokes authorization to collect or use his or her PHI, the investigator, 
by regulation, retains the ability to use all information collected prior to the revocation of patient 
authorization.  For patients that have revoked authorization to collect or use PHI, attempts should 
be made to obtain permission to collect at least vital status (i.e., that the patient is alive) at the 
end of their scheduled study period. 
In compliance with ICH Good Clinical Practice guidelines and applicable parts of 21 CFR it is a 
requirement that the investigator and institution permit authorized representatives of SCRI 
Innovations, the regulatory authorities and the IRB direct access to review the patient’s original 
medical records at the site for verification of study-related procedures and data.  
Measures to protect confidentiality include: only a unique study number and initials will identify 
patients in the eCRF or other documents submitted to SCRI Innovations.  This information, 
together with the patient’s date of birth, will be used in the database for patient identification.  
Patient names or addresses will not be entered in the eCRF.  No material bearing a patient’s 
name will be kept on file by Sponsor.  Patients will be informed of their rights within the ICF. 
13.3.1.2 Investigator and Staff Information 
Personal data of the investigators and sub-investigators may be included in the SCRI Innovations 
database, and shall be treated in compliance with all applicable laws and regulations.  When 
archiving or processing personal data pertaining to the investigator or sub investigator, SCRI 
Innovations shall take all appropriate measures to safeguard and prevent access to this data by 
any unauthorized party. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 50 of 65 
 
13.4 
Financial Information 
The finances for this clinical study will be subject to a separate written agreement between the 
SCRI Development Innovations, LLC and applicable parties.  Any Investigator financial 
disclosures as applicable to 21CFR Part 54 shall be appropriately provided. 
14. 
RESEARCH RETENTION AND DOCUMENTATION OF THE STUDY 
14.1 
Amendments to the Protocol 
Amendments to the protocol shall be planned, documented, and signature authorized prior to 
implementation. 
If an amendment to the protocol is required, the amendment will be originated and documented 
by SCRI Innovations.  All amendments require review and approval of all pharmaceutical 
companies and the Principal Investigator supporting the study.  The written amendment must be 
reviewed and approved by SCRI Innovations, and submitted to the IRB at the investigator’s 
facility for the board’s approval. 
Amendments specifically involving change to study design, risk to patient, increase to dosing or 
exposure, patient number increase, addition or removal of new tests or procedures, shall be 
reviewed and approved by the IRB of record for the Investigator’s facility. 
The amendment will be submitted formally to the FDA or other regulatory authorities by SCRI 
Innovations as applicable, and IRB approval obtained, and specifically when an increase to 
dosing or patient exposure and/or patient number has been proposed; or, when the addition or 
removal of an Investigator is necessitated. 
Items requiring a protocol amendment approval from IRB and/or FDA or other regulatory 
authorities include, but are not limited to, the following: 
• Change to study design 
• Risk to patient 
• Increase to dose or patient exposure to drug 
• Patient number increase 
• Addition or removal of tests and / or procedures 
• Addition/removal of a new Investigator 
It should be further noted that, if an amendment to the protocol substantially alters the study 
design or the potential risks to the patients, their consent to continue participation in the study 
should be obtained. 
14.2 
Documentation Required to Initiate the Study 
Before the study may begin certain documentation required by FDA regulations and ICH GCP 
must be provided by the Investigator.  The required documentation should be submitted to: 
SCRI Innovations 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 51 of 65 
 
Regulatory Department 
3322 West End Avenue, Suite 900 
Nashville, TN  37203 
Documents at a minimum required to begin a study in the US include, but are not limited to, the 
following: 
• A signature-authorized protocol and contract 
• A copy of the official IRB approval of the study and the IRB members list 
• Current Curricula Vitae for the principal investigator and any associate investigator(s) 
who will be involved in the study 
• Indication of appropriate accreditation for any laboratories to be used in the study and a 
copy of the normal ranges for tests to be performed by that laboratory 
• Original Form FDA 1572 (Statement of Investigator), appropriately completed and 
signed 
• A copy of the IRB-approved consent form (and patient information sheet, if applicable) 
containing permission for audit by representatives of  SCRI Innovations, the IRB, and the 
FDA and other regulatory agencies (as applicable) 
• Financial disclosure forms for all investigators listed on Form FDA 1572 (if applicable) 
• Site qualification reports, where applicable 
• Verification of Principal Investigator acceptability from local and/or national debarment 
list(s)  
 
14.3 
Study Documentation and Storage 
The Principal Investigator must maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties and should ensure that all persons assisting in the conduct of the study 
are informed of their obligations.  All persons authorized to make entries and/or corrections on 
the eCRFs are to be included on this document.  All entries in the patient’s eCRF are to be 
supported by source documentation where appropriate. 
Source documents are the original documents, data, records, and certified copies of original 
records of clinical findings, observations, and activities from which the patient’s eCRF data are 
obtained.  These can include, but are not limited to, hospital records, clinical and office charts, 
laboratory, medico-technical department and pharmacy records, diaries, microfiches, ECG 
traces, copies or transcriptions certified after verification as being accurate and complete, 
photographic negatives, microfilm or magnetic media, X-rays, and correspondence. 
The Principal Investigator and each study staff member is responsible for maintaining a 
comprehensive and centralized filing system (e.g., regulatory binder or investigator study file 
[ISF]) of all study-related (essential) documentation, suitable for inspection at any time by 
representatives from SCRI Innovations and/or applicable regulatory authorities.  The ISF must 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 52 of 65 
 
consist of those documents that individually or collectively permit evaluation of the conduct of 
the study and the quality of the data produced.  The ISF should contain as a minimum all 
relevant documents and correspondence as outlined in ICH GCP Section 8 and 21 CFR Part 
312.57, including key documents such as the IB and any amendments, protocol and any 
amendments, signed ICFs, copies of completed eCRFs, IRB approval documents, Financial 
Disclosure forms, patient identification lists, enrollment logs, delegation of authority log, staff 
qualification documents, laboratory normal ranges, records relating to the study drug including 
accountability records.  Drug accountability records should, at a minimum, contain information 
regarding receipt, shipment, and disposition.  Each form of drug accountability record, at a 
minimum, should contain Principal Investigator name, date drug shipped/received, date, quantity 
and batch/code, or lot number for identity of each shipment.  In addition, all original source 
documents supporting entries in the eCRF must be maintained and be readily available. 
SCRI Innovations shall maintain adequate investigational product records and financial interest 
records as per 21CFR Part 54.6 and Part 312.57 for no less than 2 years after the last marketing 
application has been approved by the FDA; or, in the event that the marketing application has not 
been approved by the FDA, for no less than 2 years after the last shipment / delivery of the drug 
for investigational use is discontinued and the FDA has been notified of the discontinuation. 
The IRB shall maintain adequate documentation / records of IRB activities as per 21CFR Part 
56.115 for at least 3 years after completion of the research. 
The Investigator shall maintain adequate records of drug disposition, case histories, and any 
other study-related records as per 21 CFR Part 312.62 for no less than 2 years after the last 
marketing application has been approved by the FDA; or, in the event that the marketing 
application has not been approved by the FDA, for no less than 2 years after the last shipment / 
delivery of the drug for investigational use is discontinued and the FDA has been notified of the 
discontinuation. 
To enable evaluations and/or audits from regulatory authorities or from SCRI Innovations or its 
representative, the investigator additionally agrees to keep records, including the identity of all 
participating patients (sufficient information to link records e.g., eCRFs, medical records), all 
original, signed ICFs, and copies of all eCRFs, SAE Reporting forms, source documents, 
detailed records of treatment disposition, and related essential regulatory documents.  The 
documents listed above must be retained by the investigator for as long as needed to comply with 
national and international regulations (generally 2 years after discontinuing clinical development 
or after the last marketing approval).  SCRI Innovations will notify the 
investigator(s)/institutions(s) when the study-related records are no longer required. 
If the investigator relocates, retires, or for any reason withdraws from the study, both SCRI 
Innovations and its representative should be prospectively notified.  The study records must be 
transferred to an acceptable designee, such as another investigator, another institution, or to 
SCRI Innovations.  The investigator must obtain SCRI Innovations written permission before 
disposing of any records, even if retention requirements have been met.  All study files will be 
SCRI Innovations throughout the study, and will be held by SCRI Innovations at the conclusion 
of the study. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 53 of 65 
 
14.4 
Data Collection 
The study eCRF is the primary data collection instrument for the study.  Case report forms will 
be completed using the English language and should be kept current to enable SCRI Innovations 
to review the patients’ status throughout the course of the study. 
In order to maintain confidentiality, only study number, patient number, initials and date of birth 
will identify the patient in the eCRF.  If the patient’s name appears on any other document (e.g., 
laboratory report), it must be obliterated on the copy of the document to be supplied to SCRI 
Innovations and replaced instead with the patient number and patient’s initials.  The investigator 
will maintain a personal patient identification list (patient numbers with corresponding patient 
identifiers) to enable records to be identified and verified as authentic.  Patient data/information 
will be kept confidential, and will be managed according to applicable local, state, and federal 
regulations. 
All data requested in the eCRF must be supported by and be consistent with the patient’s source 
documentation.  All missing data must be explained.  When a required laboratory test, 
assessment, or evaluation has not been done or an “Unknown” box is not an option on the eCRF, 
a note should be created verifying that the field was “Not Done” or “Unknown.”  For any entry 
errors made, the error(s) must be corrected, and a note explaining the reason for change should 
be provided. 
The investigator will electronically sign and date the patient eCRF casebook indicating that the 
data in the eCRF has been assessed.  Each completed eCRF will be signed and dated by the 
Principal Investigator, once all data for that patient is final. 
14.5 
Disclosure and Publication Policy 
All information provided regarding the study, as well as all information collected/documented 
during the course of the study, will be regarded as confidential.  SCRI Innovations reserves the 
right to release literature publications based on the results of the study.  Results from the study 
will be published/presented as per SCRI Innovations publication process. 
Inclusion of the investigator in the authorship of any multicenter publication will be based upon 
substantial contribution to the design, analysis, interpretation of data, drafting and/or critically 
revising any manuscript(s) derived from the study.  The investigator acknowledges that the study 
is part of a multicenter study and agrees that any publication by the investigator of the results of 
the study conducted at research site shall not be made before the first multicenter publication.  In 
the event there is no multicenter publication within fifteen (15) months after the study has been 
completed or terminated at all study sites, and all data has been received, the investigator shall 
have the right to publish its results from the study, subject to the notice requirements described 
herein and subject to acknowledgement of the funding partner as appropriate.  Investigator shall 
provide the funding partner thirty (30) days to review a manuscript or any poster presentation, 
abstract or other written or oral material which describes the results of the study for the purpose 
only of determining if any confidential or patentable information is disclosed thereby.  If the 
funding partner requests in writing, the investigator shall withhold any publication or 
presentation an additional sixty (60) days solely to permit the funding partner to seek patent 
protection and to remove any funding partner Confidential Information from all publications. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 54 of 65 
 
15. 
REFERENCES 
Ajani et al. 2004 
Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin 
chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the 
esophagus or gastroesophageal junction. Cancer. 2004;100:2347–54. 
Blot et al. 1991 
Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus 
and gastric cardia. JAMA 1991;265:1287–9. 
Devesa et al. 1998 
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and 
gastric carcinoma in the United States. Cancer 1998;83:2049–53. 
Ford et al. 2012 
Ford H, Marshall A, Wadsley J, et al. Cougar-02: A randomized phase III study of docetaxel 
versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol. 
2012; 30: (suppl 34; abstr LBA4). 
Fuchs et al. 2012 
Fuchs CS, Tomasek J, Cho JY, et al. REGARD: A phase III, randomized, double-blinded trial of 
ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or 
gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or 
fluoropyrimidine-containing combination therapy. J Clin Oncol. 2012; 30: (suppl 34; abstr LBA5). 
Lerut et al. 2004 
Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the 
esophagus and gastroesophageal junction in 174 R0 resections:  Impact on staging, disease-free 
survival, and outcome: A plea for adaptation of TNM classification in upper-half esophageal 
carcinoma. Ann Surg 2004;240:962–72; discussion 972–4. 
Lu et al. 2002 
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human 
neutralizing antibodies to VEGFR2 from a large antibody phage display library for 
antiangiogenesis therapy. Int J Cancer. 2002;97:393-9. 
Lu et al. 2003 
Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, et al. Tailoring in vitro selection for a 
picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 
for enhanced neutralizing activity. J Biol Chem. 2003;278:43496-507.  
 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 55 of 65 
 
Pera et al. 1993 
Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the 
esophagus and esophagogastric junction. Gastroenterology 1993;104:510 –3. 
Smith et al. 2006 
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of 
white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 
2006;24(19):3187–205. 
Wilke et al. 2014 
Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: A global, phase III, randomized, double-
blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of 
metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease 
progression on first-line platinum- and fluoropyrimidine-containing combination therapy 
rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol. 2014; 32, (suppl 3; abstr LBA7). 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 56 of 65 
 
16. 
APPENDICES 
 
Appendix A: ECOG Performance Status Criteria 
 
ECOG Performance Status Scale 
 
Karnofsky Performance Scale 
Grade 
Descriptions 
Percent 
Description 
0 
Normal activity. Fully active, able to carry 
on all pre-disease performance without 
restriction. 
 
100 
Normal, no complaints, no evidence of 
disease. 
 
90 
Able to carry on normal activity; minor 
signs or symptoms of disease. 
1 
Symptoms, but ambulatory.  Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light 
housework, office work). 
 
80 
Normal activity with effort; some signs or 
symptoms of disease. 
 
70 
Cares for self, unable to carry on normal 
activity or to do active work. 
2 
In bed <50% of the time.  Ambulatory and 
capable of all self-care, but unable to carry 
out any work activities.  Up and about more 
than 50% of waking hours. 
 
60 
Requires occasional assistance, but is able 
to care for most of his/her needs. 
 
50 
Requires considerable assistance and 
frequent medical care. 
3 
In bed > 50% of the time.  Capable of only 
limited self-care, confined to bed or chair 
more than 50% of waking hours. 
 
40 
Disabled, requires special care and 
assistance 
 
30 
Severely disabled, hospitalization 
indicated.  Death no imminent. 
4 
100% bedridden.  Completely disabled.  
Cannot carry on any self-care.  Totally 
confined to bed or chair. 
 
20 
Very sick, hospitalization indicated.  Death 
not imminent. 
 
10 
Moribund, fatal processes progressing 
rapidly. 
5 
Dead 
0 
Dead 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 57 of 65 
 
 
Appendix B: New York Heart Association (NYHA) Classification of Cardiac Disease 
The following table presents the NYHA classification of cardiac disease. 
Class 
Functional Capacity 
Objective Assessment 
I 
Patients with cardiac disease but without resulting limitations of physical 
activity.  Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain. 
No objective evidence of 
cardiovascular disease. 
II 
Patients with cardiac disease resulting in slight limitation of physical 
activity.  They are comfortable at rest.  Ordinary physical activity results in 
fatigue, palpitation, dyspnea, or anginal pain. 
Objective evidence of 
minimal cardiovascular 
disease. 
III 
Patients with cardiac disease resulting in marked limitation of physical 
activity.  They are comfortable at rest.  Less than ordinary activity causes 
fatigue, palpitation, dyspnea, or anginal pain. 
Objective evidence of 
moderately severe 
cardiovascular disease. 
IV 
Patients with cardiac disease resulting in inability to carry on any physical 
activity without discomfort.  Symptoms of heart failure or the anginal 
syndrome may be present even at rest.  If any physical activity is undertaken, 
discomfort is increased. 
Objective evidence of 
severe cardiovascular 
disease. 
Source:  The Criteria Committee of New York Heart Association.  Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels.  9th Ed. Boston, MA:  Little, Brown & Co; 1994:253-256. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 58 of 65 
 
Appendix C: Guidelines for Female Patients of Childbearing Potential and Fertile Male 
Patients 
 
Acceptable Contraception Methods:   
Women of childbearing potential, defined as all women physiologically capable of becoming 
pregnant, must use highly effective contraception during the study and for 3 months after 
stopping treatment.   
Highly effective contraception is defined as either: 
True Abstinence 
When this is in line with the preferred and usual lifestyle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of 
contraception. 
Sterilization  
When a woman of childbearing potential has had surgical bilateral 
oophorectomy (with or without hysterectomy) or tubal ligation at least 
six weeks prior to study entry.  In case of oophorectomy alone, only 
when the reproductive status of the woman has been confirmed by 
follow up hormone level assessment. 
Male Partner Sterilization When the appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate. 
Use of a combination of any two of the following (one from a + one from b): 
a)  Placement of an intrauterine device (IUD) or intrauterine system 
(IUS) or established use of oral, injected or implanted hormonal 
methods of contraception. 
b)  Barrier methods of contraception: Condom or Occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/vaginal suppository. 
Fertile male patients, defined as all males physiologically capable of conceiving offspring, 
with female partners of child-bearing potential must use condoms plus spermicidal agent 
during the study treatment period and for 6 months after the last dose of study drug, and 
should not father a child during this period. 
Male patients must also refrain from donating sperm during their participation in the study. 
The following are acceptable forms of barrier contraception: 
• Latex condom, diaphragm or cervical/vault cap when used with spermicidal 
foam/gel/film/cream/suppository 
Unacceptable Contraception Methods: for women of childbearing potential include: 
• IUD progesterone T 
• Female condom 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 59 of 65 
 
• Natural family planning (rhythm method) or breastfeeding 
• Fertility awareness 
• Withdrawal 
• Cervical shield 
Pregnancies 
To ensure subject safety, each pregnancy in a subject on study treatment must be reported to 
the SCRI Innovations Safety Department within 24 hours of learning of its occurrence.  The 
pregnancy should be followed up for 3 months after the termination of the pregnancy to 
determine outcome, including spontaneous or voluntary termination, details of the birth, and 
the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. 
Pregnancy should be recorded on a Clinical Study Pregnancy Form and reported by the 
investigator to SCRI Innovations Safety Department.  Pregnancy follow-up should be 
recorded on the same form and should include an assessment of the possible relationship to the 
study drug of any pregnancy outcome.  Any SAE experienced during pregnancy must be 
reported on the SAE Report Form. 
Pregnancy outcomes must be collected for the female partners of any males who took study 
treatment in this study.  Consent to report information regarding these pregnancy outcomes 
should be obtained from the mother. 
Women Not of Childbearing Potential are defined as Follows:   
• Women are considered post-menopausal and not of childbearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g., age appropriate, history of vasomotor symptoms).  
• Women who are permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy).   
• Women who are >45 years-of-age, not using hormone-replacement therapy and who 
have experienced total cessation of menses for at least 12 months OR who have a 
follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value 
<40 pg/mL (140 pmol/L). 
• Women who are >45 years-of-age, using hormone-replacement therapy and who have 
experienced total cessation of menses for at least 1 year OR who have had documented 
evidence of menopause based on FSH >40 mIU/mL and estradiol <40 pg/mL prior to 
initiation of hormone-replacement therapy. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 60 of 65 
 
Appendix D: Schedule of Assessments  
 
 
ASSESSMENTS 
Pre-
Treatment 
 
STUDY TREATMENT  (Cycles repeated every 28 days)  
FOLLOW-UP 
Day 1 
Day 8 
Day 15 
Every 2 
Cycles 
End of Study 
Treatmenth 
Disease-
Free 
Survivall 
Survivalm 
Baselinea 
Tests and Observations 
Informed consent 
X 
 
 
 
 
 
 
 
Medical history 
X 
X 
 
 
 
X 
X 
 
Physical examb    
X 
X 
 
 
 
Xb 
Xb 
 
Vital Signsc 
X 
X 
 
 
 
X 
  
 
ECOG PS  
X  
X 
 
 
 
X 
  
 
12-lead  ECG 
X 
 
  
 
 
 
 
 
Adverse event evaluation 
 
X 
X 
X 
 
X 
 
 
Concomitant medication review 
X 
X 
 
 
 
X 
 
 
Survival status 
  
 
 
 
 
 
  
X 
Laboratory Observations 
CBC, 3-part differential, and platelets 
X 
X 
X 
X 
 
X 
X 
 
CMP plus magnesium and phosphorousd 
X 
X 
 
 
 
X 
X 
 
PT, PTT, INRe  
X  
 
 
 
 
 
 
 
Urine dipstickf 
X 
X 
 
X 
 
X 
 
 
Serum or Urine Pregnancy Testg 
X 
 
  
 
 
 
 
 
CEAi 
X 
 
 
 
X 
X 
X 
 
Staging  
CT Scan Chestj 
X 
 
 
 
X 
X 
X 
 
CT Scan abdomen /pelvisk 
X 
 
 
 
X 
X 
X 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 61 of 65 
 
Appendix D: Schedule of Assessments (continued)   
 
a 
Baseline procedures including medical history, physical examination, 12-lead ECG, ECOG PS, CBC, CMP plus magnesium and phosphorous, 
PT/PTT/INR, ECG, , and  urine dipstick should be done ≤7 days prior to initiation of treatment.  However, if these initial examinations are obtained 
within 72 hours of Cycle 1 Day 1 they do not have to be repeated.  A serum or urine pregnancy test must be performed within 72 hours of Cycle 1 Day 
1. 
b 
Physical examination will include measurements of height (pretreatment visit only), weight, and vital signs.  
c 
Vital signs will include resting heart rate, blood pressure, respiratory rate, and temperature. 
d 
CMP will include measurements of glucose, BUN, creatinine, sodium, potassium, chloride, calcium, CO2, alkaline phosphatase, AST (SGOT), ALT 
(SGPT), total bilirubin, total protein, and  albumin plus magnesium and phosphorous.  CMP may be done up to 72 hours prior to treatment.     
e 
If PT/PTT or INR are normal at baseline, they do not need to be repeated.  Patients requiring the initiation of an anti-coagulation therapy during study 
treatment should have coagulation tests performed according to standard practice guidelines. 
f 
Urine dipstick (pH, protein, glucose, blood, ketones, and leukocytes)   
g 
Serum or urine pregnancy tests are to be conducted in women of childbearing potential.   
h 
Patients should visit the study center 30 days(+ 3) for end-of-treatment assessments.  Patients must be followed for AEs for 30 calendar days after the 
last dose of study drug. 
i 
CEA tumor marker will be collected≤8 weeks prior to initiation of treatment, every 2 cycles, and at the End of Study visit. 
j 
CT scans of the chest ≤8 weeks prior to initiation of treatment, every 2 cycles, and at the End of Study visit if scans were not taken in the previous 8 
weeks. 
k 
CT scans of the abdomen/pelvis ≤8 weeks prior to initiation of  treatment, every 2 cycles, and at the End of Study visit if scans were not taken in the 
previous 8 weeks.  CT Scans of the abdomen/pelvis is preferred, but CT scans of the abdomen will be accepted for CT scans of the abdomen/pelvis.   
l 
Patients discontinuing treatment for any reason other than PD will be monitored for evidence of disease progression.  Patients will be followed every 3 
months for up to 12 months after the last patient has been enrolled on study for disease progression.   
m 
Survival will be assessed in all patients at 6 and 12 months after the last patient has been enrolled on the study.  Patients may be contacted during 
outpatient visits or by telephone.  After 12 months no additional follow-up will be required. 
 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 62 of 65 
 
Appendix E: Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 
Definitions 
Response and progression will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1 (Eisenhauer et al 2009).  Lesions are either measurable or non-measurable using the criteria 
provided below.  The term “evaluable” in reference to measurability will not be used, as it does not provide 
additional meaning or accuracy. 
Baseline Eligibility 
Measurable Disease: 
Tumor lesions:  Must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a 
minimum size of: 
• 
10 mm by CT by computerized tomography (CT scan slice thickness 
no greater than 5 mm). 
• 
10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as non-
measurable). 
• 
20 mm by chest x-ray. 
 
Skin lesions:  Documentation by color photography, including a ruler to 
estimate the size of the lesion, is recommended. 
 
Malignant lymph nodes:  To be considered pathologically enlarged and 
measurable, a lymph node must be ≥15 mm in short axis when assessed by 
CT scan.  At baseline and in follow-up, only the short axis will be measured 
and followed.  
Non-Measurable Disease: 
All other lesions, including small lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥10- to <15-mm short axis) as well as truly 
non-measurable lesions.  Lesions considered truly non-measurable include: 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory 
breast disease, lymphangitic involvement of skin or lung, abdominal masses, 
abdominal organomegaly identified by physical exam that is not measurable 
by reproducible imaging techniques.  
Target Lesions: 
The most reproducible measurable lesions, up to a maximum of 2 lesions per 
organ and 5 lesions in total, representative of all involved organs should be 
identified as target lesions and recorded and measured at baseline.   
Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), should be representative of all involved organs, and in 
addition should be those that lend themselves to reproducible repeated 
measurements.  Pathological nodes which are defined as measurable and that 
may be identified as target lesions must meet the criterion or a short axis of 
≥15 mm by CT scan. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal 
lesions) for all target lesions will be calculated and reported as the baseline 
sum diameters. If lymph nodes are to be included in the sum, then as noted 
above, only the short axis is added into the sum.  The baseline sum diameters 
will be used as reference to further characterize any objective tumor 
response. 
Non-Target Lesions: 
All other lesions should be identified as non-target lesions at baseline.  
Measurements of these lesions are not required, but the presence or 
absence of each should be noted throughout follow-up. 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 63 of 65 
 
Guidelines for Evaluation of Measureable Disease 
All measurements should be taken and recorded in metric notation, using a ruler or calipers.  All baseline 
evaluations should be performed as closely as possible to the beginning of treatment, as per protocol screening 
requirements. 
The same method of assessment and the same technique should be used to characterize each identified and reported 
lesion at baseline and during follow-up.  Imaging-based evaluation is preferred to evaluation by clinical examination 
when both methods have been used to assess the anti-tumor effect of a treatment. 
 
Clinical Lesions: 
Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm in diameter.  In 
the case of skin lesions, documentation by color photography, including a 
ruler to estimate the size of the lesion, is recommended. 
Chest X-ray: 
Lesions on chest X-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, a CT scan is 
preferable. 
Conventional CT and MRI: 
CT, MRI:  CT is the best currently available and reproducible method to 
measure lesions selected for response assessment.  This guideline has 
defined measurability of lesions on CT scan based on the assumption that CT 
slice thickness is 5mm or less.  When CT scans have slice thickness greater 
than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness.  MRI is also acceptable in certain situations (e.g. for body 
scans).  
Ultrasound: 
When the primary study endpoint is objective response, ultrasound should 
not be used to measure tumor lesions.  It is, however, a possible alternative 
to clinical measurements of superficial palpable lymph nodes, subcutaneous 
lesions, and thyroid nodules.  Ultrasound may also be useful to confirm the 
complete disappearance of superficial lesions usually assessed by clinical 
examination. 
Endoscopy and Laparoscopy: 
Use of endoscopy and laparoscopy for objective tumor evaluation has not yet 
been fully and widely validated.  Therefore, use of these techniques for 
objective tumor response should be restricted to validation purposes in 
specialized centers.  Such techniques can be useful in confirming complete 
pathological response when biopsies are obtained. 
Tumor Markers: 
Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper limit of normal, they must normalize for a subject to 
be considered in complete clinical response when all lesions have 
disappeared. 
Cytology and Histology: 
Cytology and histology can be used to differentiate between partial response 
(PR) and complete response (CR) in rare cases (e.g., after treatment to 
differentiate between residual benign lesions and residual malignant lesions 
in tumor types such as germ cell tumors). 

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 64 of 65 
 
Response Criteria 
Evaluation of Target Lesions 
Complete Response (CR):  
Disappearance of all target lesions.   
Partial Response (PR):  
 
At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters. 
Stable Disease (SD):   
 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest (nadir) sum of diameters 
since the treatment started. 
Progressive Disease (PD):   
 
At least a 20% increase in the sum of the diameters of target lesions, taking 
as reference the smallest (nadir) sum since the treatment started, or the 
appearance of one or more new lesions.  Requires not only 20% increase, but 
absolute increase of a minimum of 5 mm over sum. 
 
Evaluation of Non-Target Lesions 
Complete Response (CR): 
Disappearance of all non-target lesions and normalization of tumor markers.  
All lymph nodes must be non-pathological in size (<<10 mm short axis). 
Stable Disease (SD):    
 
Persistence of one or more non-target lesions and/or persistence of tumor 
marker level above the normal limits. 
Progressive Disease (PD):  
 
Appearance of one or more new lesions and/or unequivocal progression of 
existing non-target lesions.  When the subject also has measurable disease, to 
achieve “unequivocal progression” on the basis of the non-target disease, 
there must be an overall level of substantial worsening in non-target disease 
such that, even in presence of SD or PR in the target disease, the overall 
tumor burden has increased sufficiently to merit discontinuation of therapy. 
 
Evaluation of Best Overall Response 
As detailed above, the best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).  
In general, the subject’s best response assignment will depend on the achievement of both measurement and 
confirmation criteria.   
Confirmation of response (by repeat scans after 4 weeks or as specified in the protocol) is required for studies in 
which response rate is the primary endpoint, but is not required in randomized studies or studies with primary 
survival endpoints (i.e., where response is not a primary endpoint).

 
CONFIDENTIAL 
STUDY DRUG(S):  NAB-PACLITAXEL 
  
SCRI INNOVATIONS STUDY NUMBER: GI 201 
FINAL PROTOCOL DATE:  18 NOVEMBER 2014  
 
 
 
 
VERSION 1.0 
Page 65 of 65 
 
 
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR 
NO 
CR 
CR 
SD 
NO 
PR 
CR 
NE 
NO 
PR 
PR 
SD OR NE 
NO 
PR 
SD 
SD OR NE 
NO 
SD 
PD 
ANY 
YES OR NO 
PD 
ANY 
PD 
YES OR NO 
PD 
ANY 
ANY 
YES 
PD 
 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  When the evaluation 
of a CR depends upon this determination, it is recommended that the residual lesion be investigated by fine needle 
aspirate or biopsy to confirm the CR status.  
When nodal disease is included in the sum of target lesions, and the nodes decrease to “normal” size (<10 mm), they 
may still have a measurement reported on scans.  This measurement should be recorded even though the nodes are 
normal in order not to overstate progression, should it be based on increase in size of the nodes.  As noted earlier, 
this means that subjects with CR may not have a total sum of “zero” on the eCRF.